EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part I and Castration-Resistant Prostate Cancer

European Urology

71, 630-642

DOI: 10.1016/j.eururo.2016.08.002

Citation Report

#	Article	IF	Citations
1	Metastatic Castration-resistant Prostate Cancer: Major Progress Leading to Even More Questions. European Urology Focus, 2016, 2, 562-564.	1.6	2
2	Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. European Urology Focus, 2016, 2, 463-464.	1.6	1
3	Resonancia magnÃ©tica de cuerpo entero: razones del radiÃ³logo para implantar una tÃ©cnica Ãºtil en la medicina actual. Radiologia, 2016, 58, 501-503.	0.3	1
4	Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. European Urology, 2017, 72, 521-531.	0.9	174
5	La quimioterapia no deberÃa todavÃa ser considerada en los pacientes con cÃ¡ncer de prÃ³stata metastÃ¡sico hormonosensible. Actas UrolÃ³gicas EspaÃ±olas, 2017, 41, 347-351.	0.3	0
6	Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: AÂSystematic Review of Prognostic Tool Accuracy and Validity. International Journal of Radiation Oncology Biology Physics, 2017, 98, 318-337.	0.4	10
8	PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1751-1776.	3.3	45
9	Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes. European Radiology, 2017, 27, 4828-4836.	2.3	29
11	Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer. Journal of Physical Education and Sports Management, 2017, 3, a001362.	0.5	9
12	Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2017, 20, 352-360.	2.0	69
13	Estrogen receptor Î², a regulator of androgen receptor signaling in the mouse ventral prostate. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3816-E3822.	3.3	53
14	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. British Journal of Cancer, 2017, 116, 1520-1525.	2.9	121
15	Investigational serine/threonine kinase inhibitors against prostate cancer metastases. Expert Opinion on Investigational Drugs, 2017, 26, 25-34.	1.9	1
16	Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. Targeted Oncology, 2017, 12, 401-412.	1.7	6
17	18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy. Clinical Nuclear Medicine, 2017, 42, e355-e361.	0.7	5
18	Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologistâ€™s Point of View. Journal of Nuclear Medicine, 2017, 58, 1207-1209.	2.8	4
19	Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1647-1655.	3.3	41
20	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine, 2017, 377, 352-360.	13.9	1,588

#	Article	IF	Citations
21	Lactate dehydrogenase predicts combined progressionâ€free survival after sequential therapy with abiraterone and enzalutamide for patients with castrationâ€resistant prostate cancer. Prostate, 2017, 77, 1144-1150.	1.2	29
22	Therapy assessment in prostate cancer using choline and PSMA PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 78-83.	3.3	31
23	Triptorelin 3- and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer: a profile of their use in the EU. Drugs and Therapy Perspectives, 2017, 33, 321-325.	0.3	7
24	Correlation between postoperative prostate-specific antigen and biochemical recurrence in positive surgical margin patients: Single surgeon series. Prostate International, 2017, 5, 53-58.	1.2	5
25	68 Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. Prostate International, 2017, 5, 125-129.	1.2	36
26	Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. Calcified Tissue International, 2017, 101, 111-131.	1.5	37
27	Resistance to Hormonal Therapy in Prostate Cancer. Handbook of Experimental Pharmacology, 2017, 249, 181-194.	0.9	7
28	Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. Metabolomics, 2017, 13, 52.	1.4	50
29	Radiotherapy response evaluation using FDG PET-CTâ€"established and emerging applications. British Journal of Radiology, 2017, 90, 20160764.	1.0	24
31	Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 765-775.	3.3	69
33	68 Galliumâ€"Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary andÂSecondary Staging in Prostate Cancer. Urologic Clinics of North America, 2017, 44, 557-563.	0.8	5
36	Physicochemical properties of inclusion complexes of highly soluble Î²-cyclodextrins with highly hydrophobic testosterone propionate. International Journal of Pharmaceutics, 2017, 534, 316-324.	2.6	11
37	Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study. Therapeutic Advances in Urology, 2017, 9, 179-190.	0.9	6
38	Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer. Future Oncology, 2017, 13, 1911-1913.	1.1	3
39	Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer. Drugs, 2017, 77, 1565-1576.	4.9	30
40	Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radioâ€recurrent prostate cancer. BJU International, 2017, 120, 51-58.	1.3	28
41	18 F-Choline PET/CT scan in staging and biochemical recurrence in prostate cancer patients: Changes in classification and radiotherapy planning. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 292-297.	0.1	1
42	The Role of Hormonal Treatment in Prostate Cancer. , 2017, , 333-349.		0

#	Article	IF	Citations
43	Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer. Case Reports in Oncology, 2017, 10, 627-633.	0.3	7
44	Reduced number of CD169⁺ macrophages in preâ€metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients. Prostate, 2017, 77, 1468-1477.	1.2	42
45	New aspects of molecular imaging in prostate cancer. Methods, 2017, 130, 36-41.	1.9	21
46	Role of collaboration between urologists and medical oncologists in the advanced prostate cancer space. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 665-669.	0.8	0
48	La PET/TC con 18 F-Colina en la estadificaciÃ³n y recidiva bioquÃmica de pacientes con cÃ¡ncer de prÃ³stata: cambios en la clasificaciÃ³n y planificaciÃ³n de radioterapia. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 292-297.	0.0	1
51	Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer. Scandinavian Journal of Urology, 2017, 51, 498-501.	0.6	2
52	Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. Pharmacoeconomics, 2017, 35, 1223-1236.	1.7	42
53	Salvage surgery for nodal recurrent prostate cancer. Current Opinion in Urology, 2017, 27, 604-611.	0.9	10
54	Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Current Opinion in Urology, 2017, 27, 587-595.	0.9	37
55	Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents. Medical Oncology, 2017, 34, 163.	1.2	6
56	Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy. European Urology Focus, 2017, 3, 538-544.	1.6	39
57	Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. Urology, 2017, 109, 6-18.	0.5	15
58	Castration-Resistant Prostate Cancer. Urologic Clinics of North America, 2017, 44, 647-655.	0.8	2
59	Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: a Literature Review. Current Urology Reports, 2017, 18, 63.	1.0	53
60	Prostate-Specific Membrane Antigen Positron Emission Tomographyâ€“Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning. International Journal of Radiation Oncology Biology Physics, 2017, 99, 701-709.	0.4	48
61	Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases. Expert Review of Clinical Pharmacology, 2017, 10, 809-819.	1.3	3
62	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, 2017, 17, 453.	1.1	83
64	Estradiol for the mitigation of adverse effects of androgen deprivation therapy. Endocrine-Related Cancer, 2017, 24, R297-R313.	1.6	13

#	Article	IF	Citations
65	Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time?. European Urology, 2017, 71, 349-350.	0.9	2
66	Bisphosphonates for advanced prostate cancer. The Cochrane Library, 2017, 2017, CD006250.	1.5	33
67	Testosterone suppression in the treatment of recurrent or metastatic prostate cancer â€" A Canadian consensus statement. Canadian Urological Association Journal, 2017, 12, 30-7.	0.3	16
69	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. The Cochrane Library, 0, , .	1.5	3
70	Does T1- and diffusion-weighted magnetic resonance imaging give value-added than bone scintigraphy in the follow-up of vertebral metastasis of prostate cancer?. Investigative and Clinical Urology, 2017, 58, 324.	1.0	3
71	Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial. Frontiers in Pharmacology, 2017, 8, 263.	1.6	17
72	Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel. Frontiers in Pharmacology, 2017, 8, 836.	1.6	6
73	Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?. International Journal of Molecular Sciences, 2017, 18, 2023.	1.8	8
74	Artesunate suppresses the viability and mobility of prostate cancer cells through UCA1, the sponge of miR-184. Oncotarget, 2017, 8, 18260-18270.	0.8	51
75	Concurrent treatment with simvastatin and NF-Î¹B inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-Î¹B/LIN28/let-7 miRNA signaling pathway. PLoS ONE, 2017, 12, e0184644.	1.1	31
76	Positive surgical margins and biochemical recurrence following minimally-invasive radical prostatectomy â€" An analysis of outcomes from a UK tertiary referral centre. BMC Urology, 2017, 17, 91.	0.6	33
77	The efficacy and feasibility of total reconstruction versus nontotal reconstruction of the pelvic floor on short-term and long-term urinary continence rates after radical prostatectomy: a meta-analysis. World Journal of Surgical Oncology, 2017, 15, 228.	0.8	11
78	Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer. Journal of Translational Medicine, 2017, 15, 230.	1.8	77
79	68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. Cancer Imaging, 2017, 17, 31.	1.2	20
80	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 16.	0.3	20
81	Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer. International Journal of Medical Sciences, 2017, 14, 1301-1306.	1.1	10
82	Early or delayed radiotherapy after prostatectomyâ€"who really benefits?. Translational Andrology and Urology, 2017, 6, 593-594.	0.6	1
83	Evaluation of pharmacokinetics/pharmacodynamics and efficacy of one-month depots of TAK-448 and TAK-683, investigational kisspeptin analogs, in male rats and an androgen-dependent prostate cancer model. European Journal of Pharmacology, 2018, 822, 138-146.	1.7	7

#	Article	IF	Citations
84	EvoluciÃ³n de la Medicina Nuclear en el diagnÃ³stico y tratamiento de pacientes con cÃ¡ncer de prÃ³stata. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 71-72.	0.0	0
85	Multicenter evaluation of guideline adherence for pelvic lymph node dissection in patients undergoing open retropubic vs. laparoscopic or robot assisted radical prostatectomy according to the recent German S3 guideline on prostate cancer. World Journal of Urology, 2018, 36, 855-861.	1.2	8
86	Results of 14 years of brachytherapy for localized prostate cancer in Denmark: the Herlev cohort. Scandinavian Journal of Urology, 2018, 52, 164-168.	0.6	4
87	Prospective comparative study of ¹⁸F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. Acta OncolÃ³gica, 2018, 57, 1063-1069.	0.8	9
88	Comparison of choline influx from dynamic 18F-Choline PET/CT and clinicopathological parameters in prostate cancer initial assessment. Annals of Nuclear Medicine, 2018, 32, 281-287.	1.2	9
89	Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater. Japanese Journal of Clinical Oncology, 2018, 48, 485-490.	0.6	1
91	Impact of 68 Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2018, 74, 179-190.	0.9	249
92	Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes. Surgical Oncology, 2018, 27, 138-145.	0.8	27
93	Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology. World Journal of Urology, 2018, 36, 1489-1494.	1.2	1
94	Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?. European Urology, 2018, 74, 131-133.	0.9	14
95	Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life. Cancer, 2018, 124, 2212-2219.	2.0	7
96	Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 312.e9-312.e15.	0.8	23
97	Earlier use of androgen receptorâ€axisâ€targeted drugs may improve overall survival in patients with nonâ€metastatic castrationâ€resistant prostate cancer. Prostate, 2018, 78, 766-772.	1.2	9
98	Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 361-369.	1.5	5
99	A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer. Future Oncology, 2018, 14, 1101-1115.	1.1	8
100	Performance comparison of two androgen receptor splice variant 7 (ARâ€V7) detection methods. BJU International, 2018, 122, 219-226.	1.3	11
101	Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e13-158.e20.	0.8	27
102	68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World Journal of Urology, 2018, 36, 519-527.	1.2	137

#	Article	IF	Citations
103	Plumbagin Triggers ER Stress-Mediated Apoptosis in Prostate Cancer Cells via Induction of ROS. Cellular Physiology and Biochemistry, 2018, 45, 267-280.	1.1	43
104	Intraindividual Comparison of ^{99m}Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^{99m}Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1373-1379.	2.8	31
105	Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG. Critical Reviews in Oncology/Hematology, 2018, 122, 144-149.	2.0	13
107	Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer. Clinical Oncology, 2018, 30, 93-100.	0.6	38
108	Current status of theranostics in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 471-495.	3.3	115
109	Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction. Clinical Genitourinary Cancer, 2018, 16, 197-205.e5.	0.9	7
110	Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. Journal of Nuclear Medicine, 2018, 59, 789-794.	2.8	68
111	Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 496-508.	3.3	152
112	Multiparametric Magnetic Resonance Imaging for Prostate-specific Antigen Recurrence After Radical Prostatectomy: Are We Leaving the â€œOne Treatment Fits All Approachâ€•and Moving Towards Personalized Imaging-guided Treatment?. European Urology, 2018, 73, 888-889.	0.9	4
113	Contribution of 11 C-Choline PET/CT in prostate carcinoma biochemical relapse with serum PSA level below 1 ng/ml. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 156-162.	0.1	5
114	Treatment effects in prostate cancer. Modern Pathology, 2018, 31, 110-121.	2.9	96
115	Guidelines on Radioisotope Treatment of Bone Metastases in Prostate Cancer. , 2018, , 405-413.		0
116	Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes. Memo - Magazine of European Medical Oncology, 2018, 11, 3-4.	0.3	0
117	¹⁸F-NaF/²²³RaCl₂ theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. British Journal of Radiology, 2018, 91, 20170948.	1.0	10
118	68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1862-1872.	3.3	91
119	Combined inhibition of JAK1,2/Stat3â€‘PDâ€‘L1 signaling pathway suppresses the immune escape of castrationâ€‘resistant prostate cancer to NK cells in hypoxia. Molecular Medicine Reports, 2018, 17, 8111-8120.	1.1	36
120	Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner. Cancer Chemotherapy and Pharmacology, 2018, 81, 999-1006.	1.1	19
121	Shared Decision Making in Prostate Cancer Careâ€"Encouraging Every Patient to be Actively Involved in Decision Making or Ensuring the Patient Preferred Level of Involvement?. Journal of Urology, 2018, 200, 582-589.	0.2	30

#	Article	IF	Citations
122	Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single institution experience. Clinical and Translational Radiation Oncology, 2018, 10, 29-35.	0.9	7
123	Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitive prostate cancer model. European Journal of Pharmacology, 2018, 828, 126-134.	1.7	4
125	Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptorâ€“Targeted Agents. Clinical Genitourinary Cancer, 2018, 16, e777-e784.	0.9	20
126	Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. European Journal of Endocrinology, 2018, 178, 565-576.	1.9	13
128	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. European Urology, 2018, 74, 134-137.	0.9	13
129	Dynamic contrastâ€enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience. Journal of Magnetic Resonance Imaging, 2018, 48, 1012-1023.	1.9	21
130	Bakuchiol exhibits anti-metastasis activity through NF-ÎºB cross-talk signaling with AR and ERÎ² in androgen-independent prostate cancer cells PC-3. Journal of Pharmacological Sciences, 2018, 138, 1-8.	1.1	14
131	Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 9-16.	1.0	14
132	The value of multimodality imaging in the investigation of a PSA recurrence after radical prostatectomy in the Irish hospital setting. Irish Journal of Medical Science, 2018, 187, 261-268.	0.8	1
134	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
135	Radio-223 en la secuencia terapÃ©utica del cÃ¡ncer de prÃ³stata resistente a la castraciÃ³n metastÃ¡sico. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 227-237.	0.3	2
136	Laparoscopic and robotâ€assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review. BJU International, 2018, 121, 845-853.	1.3	88
137	68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy â€“ diagnostic performance and impact on therapeutic decision-making. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 235-242.	3.3	89
138	Active surveillance for localized prostate cancer: update of a prospective single-center cohort. Scandinavian Journal of Urology, 2018, 52, 14-19.	0.6	12
139	Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade. Prostate International, 2018, 6, 18-23.	1.2	8
140	PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 12-19.	3.3	125
141	Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 20-30.	3.3	72
142	Re: Salvage High-intensity Focused Ultrasound (HIFU) for Locally Recurrent Prostate Cancer After Failed Radiation Therapy: Multi-institutional Analysis of 418 Patients. European Urology, 2018, 73, 140-141.	0.9	1

#	Article	IF	Citations
143	Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. Molecular and Cellular Endocrinology, 2018, 462, 56-63.	1.6	12
144	⁶⁴CuCl₂ PET/CT in Prostate Cancer Relapse. Journal of Nuclear Medicine, 2018, 59, 444-451.	2.8	57
145	223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases. Clinical Nuclear Medicine, 2018, 43, 9-16.	0.7	18
146	Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycleâ€"Related Transcription and Attenuated Androgen Response. Cancer Research, 2018, 78, 853-864.	0.4	90
147	Promising immunotherapy for prostate cancer. Expert Opinion on Biological Therapy, 2018, 18, 109-120.	1.4	5
148	Clinical pathway improves implementation of evidenceâ€based strategies for the management of androgen deprivation therapyâ€induced side effects in men with prostate cancer. BJU International, 2018, 121, 610-618.	1.3	10
149	Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uroâ€Oncology. BJU International, 2018, 121, 703-715.	1.3	8
150	^{99m}Tcâ€MIPâ€1404â€SPECT/CT for the detection of PSMAâ€positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate, 2018, 78, 54-63.	1.2	61
151	AportaciÃ³n de la PET/TC con 11 C-colina en la recidiva bioquÃmica del cÃ¡ncer de prÃ³stata con antÃgeno especÃfico prostÃ¡tico sÃ©rico inferior a 1 ng/ml. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 156-162.	0.0	5
153	SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clinical and Translational Oncology, 2018, 20, 57-68.	1.2	17
154	Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223. Clinical and Translational Oncology, 2018, 20, 679-686.	1.2	5
155	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. International Urology and Nephrology, 2018, 50, 71-78.	0.6	37
156	Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice. Journal of Urology, 2018, 199, 251-256.	0.2	3
157	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	0.9	60
158	Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta OncolÃ³gica, 2018, 57, 362-367.	0.8	28
159	Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG. Clinical and Translational Oncology, 2018, 20, 392-401.	1.2	1
161	Followup imaging studies in metastatic castration-resistant prostate cancer: An individualized approach. Canadian Urological Association Journal, 2018, 13, 201-202.	0.3	2
162	Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 2018, 36, 446-453.	0.8	972

#	Article	IF	Citations
163	LXRs, SHP, and FXR in Prostate Cancer: Enemies or MÃ©nage Ã Quatre With AR?. Nuclear Receptor Signaling, 2018, 15, 155076291880107.	1.0	9
164	Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 728-734.	0.7	88
167	Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scandinavian Journal of Urology, 2018, 52, 277-284.	0.6	5
168	Management of bone and metabolic effects of androgen deprivation therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 704-712.	0.8	10
169	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	5.1	90
170	Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes. Frontiers in Oncology, 2018, 8, 543.	1.3	23
171	Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study. PLoS ONE, 2018, 13, e0209049.	1.1	11
172	Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. Current Opinion in Supportive and Palliative Care, 2018, 12, 359-365.	0.5	11
173	Current Imaging Techniques for Lymph Node Staging in Prostate Cancer: A Review. Frontiers in Surgery, 2018, 5, 74.	0.6	27
174	Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. Cancers, 2018, 10, 480.	1.7	24
175	Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLoS ONE, 2018, 13, e0208063.	1.1	24
176	Quality of life in men with metastatic prostate cancer in their final years before death â€“ a retrospective analysis of prospective data. BMC Palliative Care, 2018, 17, 126.	0.8	30
177	Enzalutamide: A Review in Castration-Resistant Prostate Cancer. Drugs, 2018, 78, 1913-1924.	4.9	60
178	Inhibition of histamine receptor H3R suppresses prostate cancer growth, invasion and increases apoptosis via the AR pathway. Oncology Letters, 2018, 16, 4921-4928.	0.8	15
179	Low-frequency ultrasound enhances chemotherapy sensitivity and induces autophagy in PTX-resistant PC-3 cells via the endoplasmic reticulum stress-mediated PI3K/Akt/mTOR signaling pathway. OncoTargets and Therapy, 2018, Volume 11, 5621-5630.	1.0	31
180	Combining anticancer drugs with osteoprotective agents in prostate cancerâ€”A contemporary update. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 488-497.	0.8	0
181	Management of non-metastatic castrate-resistant prostate cancer: A systematic review. Cancer Treatment Reviews, 2018, 70, 223-231.	3.4	17
182	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	5.1	98

#	Article	IF	Citations
183	68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients. Nuclear Medicine Communications, 2018, 39, 871-880.	0.5	5
184	Metastasis Reporting and Data System for Prostate Cancer in Practice. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 527-542.	0.6	8
185	Current therapeutic options in metastatic castration-resistant prostate cancer. Seminars in Oncology, 2018, 45, 303-315.	0.8	63
186	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. The Cochrane Library, 2018, 2018, CD012816.	1.5	21
187	Natural history of castration-resistant prostate cancer in sub-Saharan African black men: a single-centre study of Nigerian men. Ecancermedicalscience, 2018, 12, 797.	0.6	3
188	Radiotherapy for newly diagnosed oligometastatic prostate cancer. Lancet, The, 2018, 392, 2327-2328.	6.3	8
189	Single-Fraction Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Relapse in Prostate Cancer. Oncology Research and Treatment, 2018, 41, 703-705.	0.8	6
190	Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer. OncoTargets and Therapy, 2018, Volume 11, 1077-1086.	1.0	10
192	Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urology, 2018, 18, 77.	0.6	2
193	RADICAL(S) Radiotherapy Post-prostatectomy, Current and Future Practice. Clinical Oncology, 2018, 30, 793-797.	0.6	0
194	Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0203400.	1.1	14
195	Predictive value of combined analysis of proâ€<scp>NPY</scp> and <scp>ERG</scp> in localized prostate cancer. Apmis, 2018, 126, 804-813.	0.9	12
196	New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors. International Journal of Molecular Sciences, 2018, 19, 2545.	1.8	10
197	Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of communityâ€based multiâ€institutional database across Japan using propensity score matching. Cancer Medicine, 2018, 7, 4893-4902.	1.3	18
198	Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. Clinical Nuclear Medicine, 2018, 43, e226-e231.	0.7	20
199	Novel nomograms for castrationâ€resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer. BJU International, 2018, 122, 994-1002.	1.3	16
200	The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide. Phytomedicine, 2018, 46, 176-183.	2.3	29
201	Diagnosis and Management of Gynecomastia for Urologists. Current Urology Reports, 2018, 19, 46.	1.0	9

#	Article	IF	Citations
202	Radio-223 en el tratamiento de metÃ¡stasis Ã³seas en pacientes con cÃ¡ncer de prÃ³stata resistente a la castraciÃ³n. RevisiÃ³n de la literatura y procedimiento. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 330-337.	0.0	5
203	Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. Cancer Treatment and Research Communications, 2018, 16, 18-23.	0.7	4
204	Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castrationâ€resistant prostate cancer. BJU International, 2018, 122, 695-704.	1.3	7
205	Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. Expert Opinion on Investigational Drugs, 2018, 27, 553-559.	1.9	18
206	Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1873-1883.	3.3	41
207	Lu-177-PSMA treatment for metastatic prostate cancer: case examples of major responses. Clinical and Translational Imaging, 2018, 6, 223-237.	1.1	5
208	Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis. Prostate International, 2018, 6, 119-125.	1.2	6
209	Risk of secondary rectal cancer and colon cancer after radiotherapy for prostate cancer: a meta-analysis. International Journal of Colorectal Disease, 2018, 33, 1149-1158.	1.0	13
210	The effects of flutamide on cell-cell junctions in the testis, epididymis, and prostate. Reproductive Toxicology, 2018, 81, 1-16.	1.3	27
211	68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2035-2044.	3.3	72
212	Landmarks in prostate cancer. Nature Reviews Urology, 2018, 15, 627-642.	1.9	78
213	Performance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2062-2070.	3.3	13
214	Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches. Radiation Oncology, 2018, 13, 98.	1.2	19
215	Marital status independently predicts prostate cancer survival in men who underwent radical prostatectomy: An analysis of 95,846 individuals. Oncology Letters, 2018, 15, 4737-4744.	0.8	25
216	Molecular underpinnings of enzalutamide resistance. Endocrine-Related Cancer, 2018, 25, R545-R557.	1.6	28
217	Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer. Scientific Reports, 2018, 8, 10407.	1.6	22
218	Salvage CyberKnife-Based Reirradiation of Patients With Recurrent Prostate Cancer: The Single-Center Experience. Technology in Cancer Research and Treatment, 2018, 17, 153303381878549.	0.8	20
219	Immediate vs. Delayed ADT for Recurrent Prostate Cancer. , 2018, , 117-120.		0

#	Article	IF	Citations
220	Role of Radical Prostatectomy in the Management of Metastatic Prostate Cancer. , 2018, , 59-63.		2
221	Construction of a Preoperative Radiologic-Risk Signature for Predicting the Pathologic Status of Prostate Cancer at Radical Prostatectomy. American Journal of Roentgenology, 2018, 211, 805-811.	1.0	1
222	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2018, 129, 377-386.	0.3	39
223	Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis. Yonsei Medical Journal, 2018, 59, 580.	0.9	9
225	The role of ketoconazole in current prostate cancer care. Nature Reviews Urology, 2018, 15, 643-651.	1.9	48
226	Positronâ€emission tomography imaging in urological oncology: Current aspects and developments. International Journal of Urology, 2018, 25, 912-921.	0.5	10
227	Nuclear Medicine Imaging of Prostate Cancer in the Elderly. Seminars in Nuclear Medicine, 2018, 48, 541-547.	2.5	6
228	Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 332-340.	0.9	64
229	Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of â€˜real-lifeâ€™ studies. Therapeutic Advances in Urology, 2018, 10, 305-315.	0.9	16
230	Management of Nonmetastatic Failure Following Local Prostate Cancer Therapy. , 2018, , 1-14.		0
231	Androgen receptor: what we know and what we expect in castration-resistant prostate cancer. International Urology and Nephrology, 2018, 50, 1753-1764.	0.6	16
232	Comparison Between 64Cu-PSMA-617 PET/CT and 18F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. Clinical Genitourinary Cancer, 2018, 16, 385-391.	0.9	33
233	Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1884-1897.	3.3	76
234	Advances in Urologic Imaging. Urologic Clinics of North America, 2018, 45, 503-524.	0.8	27
235	Radium-223 in the treatment of bone metastases in patients with castration-resistant prostate cancer. Review and procedure. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 330-337.	0.1	2
236	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. Clinical Genitourinary Cancer, 2018, 16, 318-324.	0.9	4
237	Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer. European Urology Oncology, 2018, 1, 3-18.	2.6	10
238	Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. European Urology Oncology, 2018, 1, 46-53.	2.6	53

#	Article	IF	Citations
239	68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5Âng/ml. Efficacy and impact on treatment strategy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 11-19.	3.3	96
240	Targeting prostate cancer: Prostateâ€specific membrane antigen based diagnosis and therapy. Medicinal Research Reviews, 2019, 39, 40-69.	5.0	88
241	First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 148-158.	3.3	78
242	Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. World Journal of Urology, 2019, 37, 2565-2571.	1.2	10
243	Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Molecular Imaging and Biology, 2019, 21, 558-566.	1.3	22
244	Robotic laparoendoscopic single-site radical prostatectomy (R-LESS-RP) with daVinci Single-SiteÂ® platform. Concept and evolution of the technique following an IDEAL phase 1. Journal of Robotic Surgery, 2019, 13, 215-226.	1.0	17
245	Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis. Clinical and Translational Oncology, 2019, 21, 314-323.	1.2	17
246	Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer. World Journal of Urology, 2019, 37, 457-467.	1.2	19
247	Baseline 18F-Fluorocholine PET/CT and bone scan in the outcome prediction of patients treated with radium 223 dichloride. Clinical and Translational Oncology, 2019, 21, 289-297.	1.2	10
248	Current Management of pT3b Prostate Cancer After Robot-assisted Laparoscopic Prostatectomy. European Urology Oncology, 2019, 2, 110-117.	2.6	13
249	Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. World Journal of Urology, 2019, 37, 2607-2613.	1.2	18
250	Treatment patterns of prostate cancer with bone metastasis in Beijing: A realâ€world study using data from an administrative claims database. Pharmacoepidemiology and Drug Safety, 2019, 28, 1501-1509.	0.9	5
251	Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation. Genes, 2019, 10, 599.	1.0	17
252	Early Dutasteride Monotherapy in Patients With Elevated Serum Prostate-Specific Antigen Levels Following Robot-Assisted Radical Prostatectomy. Frontiers in Oncology, 2019, 9, 691.	1.3	2
253	Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?. Prostate, 2019, 79, 1673-1682.	1.2	7
254	The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy. Journal of Cancer, 2019, 10, 3102-3111.	1.2	27
255	Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 637-646.	0.8	28
256	Development and validation of prognostic nomograms for patients with metastatic prostate cancer. International Urology and Nephrology, 2019, 51, 1743-1753.	0.6	10

#	Article	IF	Citations
257	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. European Urology, 2019, 76, 732-739.	0.9	99
258	GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Molecular Cancer Therapeutics, 2019, 18, 1811-1821.	1.9	11
259	68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Annals of Nuclear Medicine, 2019, 33, 766-775.	1.2	35
260	Functional outcomes of artificial urinary sphincter implantation with distal bulbar double cuff in men with and without a history of external beam radiotherapy: an analysis of a prospective database. BJU International, 2019, 124, 1040-1046.	1.3	9
261	Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis. Canadian Urological Association Journal, 2019, 14, 36-41.	0.3	5
262	Salvage radiation therapy following radical prostatectomy in Stockholm County in 2008â€“2016. Journal of Radiation Oncology, 2019, 8, 225-231.	0.7	0
263	Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study. Japanese Journal of Clinical Oncology, 2019, 49, 1157-1163.	0.6	17
264	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2169-2177.	3.3	30
265	Phytochemicals in Prostate Cancer: From Bioactive Molecules to Upcoming Therapeutic Agents. Nutrients, 2019, 11, 1483.	1.7	59
266	Enhancing PSMA-uptake with androgen deprivation therapy â€“ a new way to detect prostate cancer metastases?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 459-467.	0.7	18
267	Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncology, The, 2019, 20, 1740-1749.	5.1	147
268	Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiation Oncology, 2019, 14, 177.	1.2	13
269	Enzalutamide in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 1493-1495.	13.9	4
270	Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 964-969.	0.8	2
271	Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients. Journal of Cancer, 2019, 10, 5608-5613.	1.2	31
273	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Oncology, 2021, 4, 618-627.	2.6	6
274	Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharmaceutical Research, 2019, 36, 181.	1.7	4
275	A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature. Cancers, 2019, 11, 1603.	1.7	28

#	Article	IF	Citations
277	Patientsâ€™ and partnersâ€™ views of care and treatment provided for metastatic castrateâ€resistant prostate cancer in the UK. European Journal of Cancer Care, 2019, 28, e13140.	0.7	7
278	ï»¿68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. Nuklearmedizin - NuclearMedicine, 2019, 58, 352-362.	0.3	9
279	Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study . Research and Reports in Urology, 2019, Volume 11, 215-221.	0.6	1
280	Liquid Biopsy in Oligometastatic Prostate Cancerâ€"A Biologist's Point of View. Frontiers in Oncology, 2019, 9, 775.	1.3	21
281	Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy. PET Clinics, 2019, 14, 487-498.	1.5	2
282	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.4	37
283	Radioablation +/â˜ hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). BMC Cancer, 2019, 19, 903.	1.1	9
284	High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 476-479.	0.9	1
285	Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis. Journal of Clinical Pathology, 2019, 72, 696-704.	1.0	5
286	A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Scandinavian Journal of Urology, 2019, 53, 312-318.	0.6	5
288	Elastic fusion biopsy versus systematic biopsy for prostate cancer detection: Results of a multicentric study on 1119 patients. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2019, 43, 431-438.	0.2	2
289	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Scientific Reports, 2019, 9, 13786.	1.6	44
290	Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MR-HIFU): Overview of Emerging Applications (Part 2). RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2019, 191, 531-539.	0.7	19
291	Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis. Oncogene, 2019, 38, 3696-3709.	2.6	26
292	Detection Rate of ¹⁸F-Choline PET/CT and ⁶⁸Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes. Journal of Nuclear Medicine, 2019, 60, 971-977.	2.8	35
293	Safety and Image Quality of 1.5-T Endorectal Coil Multiparametric MRI of the Prostate or Prostatectomy Fossa for Patients With Pacemaker or Implantable Cardioverter-Defibrillator. American Journal of Roentgenology, 2019, 212, 815-822.	1.0	3
294	Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes. World Journal of Urology, 2019, 37, 1507-1515.	1.2	16
295	Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. Therapeutic Advances in Urology, 2019, 11, 175628721882080.	0.9	2

#	Article	IF	Citations
296	Comparison of bone lesion distribution between prostate cancer and multiple myeloma with whole-body MRI. Diagnostic and Interventional Imaging, 2019, 100, 295-302.	1.8	8
297	Should we involve patients more actively? Perspectives of the multidisciplinary team on shared decision-making for older patients with metastatic castration-resistant prostate cancer. Journal of Geriatric Oncology, 2019, 10, 653-658.	0.5	17
298	Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer. Lab on A Chip, 2019, 19, 87-97.	3.1	56
299	Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel. Contrast Media and Molecular Imaging, 2019, 2019, 1-7.	0.4	4
300	The impact of <scp>prostateâ€specific antigen</scp> persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer. BJU International, 2019, 124, 785-791.	1.3	20
301	Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1911-1918.	3.3	55
302	Biomarkers of Prostate Cancer. , 2019, , 125-132.		0
303	Patterns and predictors of registration and participation at a supportive care program for prostate cancer survivors. Supportive Care in Cancer, 2019, 27, 4363-4373.	1.0	5
304	Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies. Drugs and Aging, 2019, 36, 701-717.	1.3	14
305	Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide populationâ€based propensity score matching study. Cancer Medicine, 2019, 8, 4475-4483.	1.3	7
307	Radiotherapy for prostate cancer: DISCERN quality assessment of patient-oriented websites in 2018. BMC Urology, 2019, 19, 42.	0.6	10
308	No evidence of association between psychological distress and pain relief in patients with bone metastases from castrationâ€resistant prostate cancer treated with 223Radium. European Journal of Cancer Care, 2019, 28, e13112.	0.7	7
309	Salvage highâ€intensity focused ultrasound for locally recurrent prostate cancer after lowâ€doseâ€rate brachytherapy: oncological and functional outcomes. BJU International, 2019, 124, 746-757.	1.3	15
310	Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 237-245.	0.7	4
311	Postoperative elective pelvic nodal irradiation compared to prostate bed irradiation in locally advanced prostate cancer â€“ a retrospective analysis of dose-escalated patients. Radiation Oncology, 2019, 14, 96.	1.2	2
312	Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI. Medical Oncology, 2019, 36, 67.	1.2	13
313	Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 485-491.	0.8	18
314	Simvastatin delays castrationâ€resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolinâ€1. International Journal of Oncology, 2019, 54, 2054-2068.	1.4	11

#	Article	IF	Citations
315	Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer. Molecular Cancer Research, 2019, 17, 1699-1709.	1.5	19
316	Oligometastases in prostate cancer: Ablative treatment. World Journal of Clinical Oncology, 2019, 10, 38-51.	0.9	27
317	(68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2019, 23, 194-200.	0.6	19
318	Multidisciplinary Team Meetings for Prostate Cancer Treatment: We Can Do Much Better in Daily Life. Oncology Research and Treatment, 2019, 42, 363-365.	0.8	8
319	Radical prostatectomy or radiotherapy for highâ€•and very highâ€risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU International, 2019, 124, 811-819.	1.3	28
320	Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axisâ€“Targeted Agents. Clinical Genitourinary Cancer, 2019, 17, 223-230.	0.9	13
321	Remarkable response to abiraterone acetate in castrationâ€resistant prostate cancer patient with aggressive liver metastasis. IJU Case Reports, 2019, 2, 12-14.	0.1	0
323	The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. Prostate, 2019, 79, 1065-1070.	1.2	27
324	Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients. Journal of Endourology, 2019, 33, 570-575.	1.1	10
326	Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of Î²-catenin in cancer stem-like cells. EBioMedicine, 2019, 42, 397-407.	2.7	63
327	68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy. World Journal of Urology, 2019, 37, 1535-1542.	1.2	23
328	Molecular Imaging and Theranosticsâ€”A Multidisciplinary Approach. Seminars in Nuclear Medicine, 2019, 49, 247-254.	2.5	19
329	Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases. Clinical Genitourinary Cancer, 2019, 17, e612-e617.	0.9	3
330	Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence. Tumori, 2019, 105, 277-281.	0.6	6
331	Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness. Tumor Biology, 2019, 41, 101042831982722.	0.8	10
332	Intention-to-Treat Analysis of ⁶⁸Ga-PSMA and ¹¹C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. Journal of Nuclear Medicine, 2019, 60, 1359-1365.	2.8	29
333	Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. World Journal of Urology, 2019, 37, 1543-1549.	1.2	19
334	The value of a bladder-filling protocol for patients with prostate cancer who receive post-operative radiation: results from a prospective clinical trial. Acta OncolÃ³gica, 2019, 58, 463-468.	0.8	13

#	Article	IF	Citations
335	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	1.2	69
336	A multicenter observational study of the realâ€world use of docetaxel for metastatic castrationâ€resistant prostate cancer in China. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 144-150.	0.7	5
337	Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases. International Journal of Clinical Oncology, 2019, 24, 557-566.	1.0	10
338	Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review. World Journal of Urology, 2019, 37, 1469-1483.	1.2	23
339	Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 614-621.	0.4	22
340	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. European Urology, 2019, 76, 517-523.	0.9	81
341	RadiothÃ©rapie interne vectorisÃ©e par 177Lu-PSMA-617Âde lâ€™adÃ©nocarcinome prostatique mÃ©tastatique rÃ©sistant Ã la castrationÂ: Ã propos dâ€™un cas et revue de la littÃ©rature. Medecine Nucleaire, 2019, 43, 298-303.	0.2	0
342	The role of hormone therapy and chemotherapy in oligometastatic prostate cancer. ESMO Open, 2019, 4, e000471.	2.0	11
343	Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology, 2019, 138, 24-28.	2.0	32
344	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. European Urology, 2019, 76, 179-186.	0.9	15
345	Efficient Prostate Cancer Therapy with Tissue-Specific Homing Peptides Identified by Advanced Phage Display Technology. Molecular Therapy - Oncolytics, 2019, 12, 138-146.	2.0	14
348	Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 408-419.	5.1	276
349	Radionuclide intake risks in the clinical administration of ²²³RaCl₂. Journal of Radiological Protection, 2019, 39, 387-398.	0.6	4
350	SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy. International Urology and Nephrology, 2019, 51, 443-451.	0.6	15
352	Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 729-742.	1.4	7
353	Evaluation of whole-body tumor burden with 68Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer. Annals of Nuclear Medicine, 2019, 33, 344-350.	1.2	18
354	Safety and outcomes of new generation hormone-therapy in elderly chemotherapy-naive metastatic castration-resistant prostate cancer patients in the real world. Archives of Gerontology and Geriatrics, 2019, 82, 179-185.	1.4	15
355	Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy. Annals of Nuclear Medicine, 2019, 33, 326-332.	1.2	8

#	Article	IF	Citations
356	Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. Scandinavian Journal of Urology, 2019, 53, 34-39.	0.6	30
357	Impact of access to novel therapies on the initial management of castrateâ€resistant prostate cancer: an Australian multicentre study. Internal Medicine Journal, 2019, 49, 1378-1385.	0.5	4
358	Cytoreductive prostatectomy: what is the evidence? A systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 1-8.	3.9	9
359	PCASTt/SPCG-17â€"a randomised trial of active surveillance in prostate cancer: rationale and design. BMJ Open, 2019, 9, e027860.	0.8	19
360	Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA â‰¥4 ng/mL: a systematic review and meta-analysis. Translational Andrology and Urology, 2019, 8, 741-753.	0.6	7
362	Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2019, 43, 562-567.	0.2	0
363	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. European Urology Oncology, 2019, 2, 152-162.	2.6	29
364	TGF-Î² and microRNA Interplay in Genitourinary Cancers. Cells, 2019, 8, 1619.	1.8	19
365	Tumors of the Male Reproductive System. , 2019, , 626-644.		0
366	Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer. Cancers, 2019, 11, 1788.	1.7	3
367	Quality of Life and Decision Regret After Postoperative Radiation Therapy to the Prostatic Bed Region With or Without Elective Pelvic Nodal Radiation Therapy. Practical Radiation Oncology, 2019, 9, e516-e527.	1.1	1
368	Effect of positive carbon-11-choline PET/CT results in the therapeutic management of prostate cancer biochemical relapse. Nuclear Medicine Communications, 2019, 40, 79-85.	0.5	7
369	Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. Nuclear Medicine Communications, 2019, 40, 940-946.	0.5	36
370	CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines. Current Urology, 2019, 13, 157-165.	0.4	22
371	Automated acquisition of explainable knowledge from unannotated histopathology images. Nature Communications, 2019, 10, 5642.	5.8	92
372	Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer. Medicine (United States), 2019, 98, e16193.	0.4	9
373	PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance. Anti-Cancer Drugs, 2019, 30, 722-730.	0.7	12
374	Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data. Prostate Cancer and Prostatic Diseases, 2019, 22, 150-158.	2.0	6

#	Article	IF	Citations
375	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	1.2	21
376	Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patients. Modern Pathology, 2019, 32, 122-127.	2.9	16
377	TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 1766-1773.	3.2	117
378	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. European Urology, 2019, 75, 548-551.	0.9	36
379	Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. Clinical Genitourinary Cancer, 2019, 17, 79-87.	0.9	18
380	Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 181.e1-181.e6.	0.8	18
381	Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. International Journal of Radiation Oncology Biology Physics, 2019, 103, 229-240.	0.4	24
382	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 123-129.	0.8	10
383	Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe. European Urology Focus, 2019, 5, 155-158.	1.6	13
384	The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone. In Vivo, 2019, 33, 99-108.	0.6	11
385	Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer. Journal of Bioinformatics and Computational Biology, 2019, 17, 1950003.	0.3	16
386	Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World Journal of Urology, 2019, 37, 2557-2564.	1.2	23
387	Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). British Journal of Radiology, 2019, 92, 20180494.	1.0	50
388	Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uroâ€oncologists' opinions and practice. International Journal of Clinical Practice, 2019, 73, 1-6.	0.8	3
389	Re: [177Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study. European Urology, 2019, 75, 536-537.	0.9	2
390	A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e203-e208.	0.9	6
391	Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study. BMC Cancer, 2019, 19, 60.	1.1	33
392	Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate, 2019, 79, 583-591.	1.2	21

#	Article	IF	Citations
393	Identification a novel set of 6 differential expressed genes in prostate cancer that can potentially predict biochemical recurrence after curative surgery. Clinical and Translational Oncology, 2019, 21, 1067-1075.	1.2	18
394	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. Nature Reviews Urology, 2019, 16, 159-171.	1.9	62
395	Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. Journal of Nuclear Medicine, 2019, 60, 1111-1117.	2.8	23
396	Combined Nâ€terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells. Prostate, 2019, 79, 206-214.	1.2	18
397	68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 31-39.	3.3	74
398	Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis. Clinical Genitourinary Cancer, 2019, 17, e19-e25.	0.9	15
399	Impact of sodium 18F-fluoride PET/CT, 18F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study. World Journal of Urology, 2019, 37, 1587-1595.	1.2	10
400	Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. European Urology, 2019, 76, 493-504.	0.9	111
401	Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta OncolÃ³gica, 2019, 58, 110-118.	0.8	4
402	Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews. Patient, 2019, 12, 57-67.	1.1	22
403	Impact of ⁶⁸Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. Journal of Nuclear Medicine, 2019, 60, 963-970.	2.8	44
404	Effect of early salvage radiotherapy at PSAâ€‰<â€‰0.5â€‰ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 344-349.	2.0	17
405	Abiraterone and spironolactone in prostate cancer: a combination to avoid. Acta Clinica Belgica, 2019, 74, 439-444.	0.5	14
406	Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. Prostate Cancer and Prostatic Diseases, 2019, 22, 206-220.	2.0	19
407	Tumor markers: myths and facts unfolded. Abdominal Radiology, 2019, 44, 1575-1600.	1.0	28
408	Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. Cancer Treatment Reviews, 2019, 73, 54-61.	3.4	28
409	Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 889-900.	3.3	44
410	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. European Urology, 2019, 75, 176-183.	0.9	101

#	Article	IF	Citations
411	Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. Clinical and Translational Oncology, 2019, 21, 420-432.	1.2	6
412	Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. European Urology, 2019, 75, 410-418.	0.9	375
413	Survival analysis and development of a prognostic nomogram for boneâ€metastatic prostate cancer patients: A singleâ€center experience in Indonesia. International Journal of Urology, 2019, 26, 83-89.	0.5	9
414	Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up. European Urology, 2019, 75, 208-214.	0.9	20
415	Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth. European Urology Focus, 2019, 5, 81-89.	1.6	17
416	Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study. European Urology Focus, 2019, 5, 1007-1013.	1.6	79
417	Does 1.5ÂT mpMRI play a definite role in detection of clinically significant prostate cancer? Findings from a prospective study comparing blind 24-core saturation and targeted biopsies with a novel data remodeling model. Aging Clinical and Experimental Research, 2019, 31, 115-123.	1.4	3
418	ALDH1A1 in patientâ€derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression. International Journal of Cancer, 2020, 146, 1099-1113.	2.3	30
419	Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer and Prostatic Diseases, 2020, 23, 24-37.	2.0	37
420	Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. International Journal of Cancer, 2020, 146, 161-168.	2.3	54
421	Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. Clinical Genitourinary Cancer, 2020, 18, 155-160.	0.9	13
422	Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2020, 23, 1-10.	2.0	30
423	Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy. World Journal of Urology, 2020, 38, 971-979.	1.2	2
424	Drug-Drug Interactions in Prostate Cancer Treatment. Clinical Genitourinary Cancer, 2020, 18, e71-e82.	0.9	13
425	A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients. World Journal of Urology, 2020, 38, 111-119.	1.2	5
426	The new ISUP 2014/WHO 2016 prostate cancer grade group system: first rÃ©sumÃ© 5Âyears after introduction and systemic review of the literature. World Journal of Urology, 2020, 38, 657-662.	1.2	12
427	Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. European Urology Oncology, 2020, 3, 455-463.	2.6	17
428	Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxelâ€"A pooled analysis of 3 randomized studies. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 210-215.	0.8	9

#	Article	IF	Citations
429	‹sup›68‹/sup›Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery. Acta OncolÃ³gica, 2020, 59, 149-156.	0.8	9
430	Postoperative biochemical recurrence of pathologically localized high-grade prostate cancer in adjuvant treatment-naÃ¯ve patients. Journal of Cancer Research and Clinical Oncology, 2020, 146, 221-227.	1.2	1
431	[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 185-191.	3.3	16
432	Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e157-e166.	0.9	21
433	Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. World Journal of Urology, 2020, 38, 1757-1764.	1.2	6
434	MicroRNAâ€140 inhibit prostate cancer cell invasion and migration by targeting YES protoâ€oncogene 1. Journal of Cellular Biochemistry, 2020, 121, 482-488.	1.2	8
435	Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2020, 25, 479-485.	1.0	1
436	PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients. Seminars in Nuclear Medicine, 2020, 50, 98-109.	2.5	37
437	First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 123-135.	3.3	81
438	Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for ‹sup›18‹/sup›F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 210-216.	2.8	10
439	Change patterns and determinants of physical activity differ between breast, prostate, and colorectal cancer patients. Supportive Care in Cancer, 2020, 28, 3207-3218.	1.0	19
440	Reply to Pirus Ghadjar, Thomas Wiegelâ€™s Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. Eur Urol 2019;76:732â€“9. European Urology, 2020, 77, e62-e63.	0.9	2
441	LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p. Cellular Signalling, 2020, 65, 109422.	1.7	92
442	Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer. Clinical Oncology, 2020, 32, 259-265.	0.6	17
443	Anti-androgen hormonal therapy for cancer and other diseases. European Journal of Pharmacology, 2020, 866, 172783.	1.7	38
444	Clinical characteristics and outcomes of robot-assisted laparoscopic radical prostatectomy in HIV-positive patients: a nationwide population-based analysis. International Urology and Nephrology, 2020, 52, 481-487.	0.6	3
445	Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer and Prostatic Diseases, 2020, 23, 269-276.	2.0	68
447	Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clinical Chemistry and Laboratory Medicine, 2020, 58, 326-339.	1.4	123

#	Article	IF	Citations
448	Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. BJU International, 2020, 125, 417-425.	1.3	24
449	An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy. Internal Medicine, 2020, 59, 395-399.	0.3	0
450	Response assessment using [⁶⁸Ga]Gaâ€PSMA ligand PET in patients undergoing systemic therapy for metastatic castrationâ€resistant prostate cancer. Prostate, 2020, 80, 74-82.	1.2	49
451	The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experience. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 38.e9-38.e16.	0.8	3
452	Renal outcomes of radioligand therapy: experience of 177lutetiumâ€"prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer. CKJ: Clinical Kidney Journal, 2020, 13, 1049-1055.	1.4	29
453	Observer Agreement and Accuracy of ¹⁸F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 344-349.	2.8	16
454	New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 687-694.	3.3	38
455	METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e391-e396.	0.9	12
456	68Ga-PSMA PET/CT Uptake in the Ureter Caused by Ligand Expression in Urothelial Cancer. Clinical Nuclear Medicine, 2020, 45, e43-e45.	0.7	7
457	A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy. Journal of Oncology Pharmacy Practice, 2020, 26, 1254-1258.	0.5	4
458	Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer. Cell Death and Differentiation, 2020, 27, 1938-1951.	5.0	37
459	18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 592-602.	3.3	26
460	The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 632-641.	3.3	27
461	Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol 2019;76:732â€"9. European Urology, 2020, 77, e60-e61.	0.9	1
463	Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study. Clinical Genitourinary Cancer, 2020, 18, 185-191.	0.9	8
464	Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. World Journal of Urology, 2020, 38, 2501-2511.	1.2	9
465	Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease. Current Opinion in Urology, 2020, 30, 90-97.	0.9	15
466	Role of Lipoproteins in the Microenvironment of Hormone-Dependent Cancers. Trends in Endocrinology and Metabolism, 2020, 31, 256-268.	3.1	15

#	Article	IF	Citations
467	The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies. Epidemiology, 2020, 31, 432-440.	1.2	22
468	Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer. Current Opinion in Urology, 2020, 30, 98-105.	0.9	22
469	Extracellular vesicles in urological malignancies: an update. Nature Reviews Urology, 2020, 17, 11-27.	1.9	79
470	Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 652-664.	3.3	38
471	Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levelsâ€‰â‰‰â€‰2.0â€‰ng/ml. Prostate Cancer and Prostatic Diseases, 2020, 23, 343-348.	2.0	30
472	Should all prostate needle biopsy Gleason score 4â€¯+â€¯4â€¯=â€¯8 prostate cancers be high risk? Implications for shared decision-making and patient counselling. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 78.e1-78.e6.	0.8	6
473	Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 8.	1.7	18
474	Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences. Clinical Nuclear Medicine, 2020, 45, 668-671.	0.7	3
475	Dual-Time Point [68Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer. Cancers, 2020, 12, 2788.	1.7	27
476	Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database. Cancer Epidemiology, 2020, 69, 101833.	0.8	14
477	99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 2020, 45, e349-e357.	0.7	15
478	Inter- and intraobserver agreement in standard and ultra-fast single-photon emission computed tomography/computed tomography for the assessment of bone metastases. Nuclear Medicine Communications, 2020, 41, 1005-1009.	0.5	5
479	Oncological safety and functional outcomes of testosterone replacement therapy in symptomatic adult-onset hypogonadal prostate cancer patients following robot-assisted radical prostatectomy. World Journal of Urology, 2021, 39, 3223-3229.	1.2	8
480	Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer. Frontiers in Oncology, 2020, 10, 549220.	1.3	3
481	Long Non-Coding RNA DARS-AS1 Contributes to Prostate Cancer Progression Through Regulating the MicroRNA-628-5p/MTDH Axis . Cancer Management and Research, 2020, Volume 12, 8363-8377.	0.9	7
482	Indications and Complications of Androgen Deprivation Therapy. Seminars in Oncology Nursing, 2020, 36, 151042.	0.7	3
483	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. Urologic Clinics of North America, 2020, 47, 487-510.	0.8	10
484	Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving ¹⁷⁷Lu-PSMA-617 Radioligand Therapy. Theranostics, 2020, 10, 7645-7655.	4.6	23

#	Article	IF	Citations
485	Real-world efficacy and safety of two doses of cabazitaxel (20 or 25â€‰mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study. BMC Cancer, 2020, 20, 649.	1.1	3
486	Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1881-1891.	1.0	8
487	Use of bisphosphonates and other bone supportive agents in the management of prostate cancerâ€”A UK perspective. International Journal of Clinical Practice, 2020, 74, e13611.	0.8	0
488	Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer. Translational Andrology and Urology, 2020, 9, 1937-1944.	0.6	15
489	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. European Urology Oncology, 2021, 4, 745-754.	2.6	17
490	Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer. Frontiers in Oncology, 2020, 10, 551491.	1.3	0
491	Matched-Pair Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Nonâ€“Tumor-Related Uptake and Tumor Positivity. Journal of Nuclear Medicine, 2021, 62, 1082-1088.	2.8	36
492	Prognostic Value of 18F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223. Biomedicines, 2020, 8, 555.	1.4	9
493	Postoperative Biochemical Failure in Patients With PI-RADS Category 4 or 5 Prostate Cancers: Risk Stratification According to Zonal Location of an Index Lesion. American Journal of Roentgenology, 2020, 215, 913-919.	1.0	10
494	Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer . Cancer Management and Research, 2020, Volume 12, 5667-5676.	0.9	15
495	Magnetically Directed Enzyme/Prodrug Prostate Cancer Therapy Based on Î²-Glucosidase/Amygdalin . International Journal of Nanomedicine, 2020, Volume 15, 4639-4657.	3.3	21
496	Role of microRNAs in the development, prognosis and therapeutic response of patients with prostate cancer. Gene, 2020, 759, 144995.	1.0	14
497	Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. Cancer Treatment Reviews, 2020, 89, 102069.	3.4	32
498	Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: a critical review. Translational Andrology and Urology, 2020, 9, 1415-1427.	0.6	9
499	Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?. Cancer Imaging, 2020, 20, 58.	1.2	10
500	Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-resistant Prostate Cancer and Risk of Cardiovascular Toxicity: All That Glitters Isnâ€™t Gold. European Urology, 2020, 78, 647-649.	0.9	2
501	Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 2091-2099.	0.9	8
502	Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 581515.	1.3	27

#	Article	IF	Citations
503	Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines. Molecular Biology Reports, 2020, 47, 7675-7683.	1.0	3
504	B7-1 and GM-CSF enhance the anti-tumor immune effect of DC-tumor fusion vaccine in the treatment of prostate cancer. Medical Oncology, 2020, 37, 107.	1.2	5
505	The role of salvage lymph node dissection and PSMA-PET in recurrent prostate cancer. Gland Surgery, 2020, 9, 1080-1081.	0.5	0
506	Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial. World Journal of Urology, 2021, 39, 2439-2446.	1.2	26
507	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 383-400.	0.4	4
508	Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors. International Journal of Molecular Sciences, 2020, 21, 7812.	1.8	8
509	Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target. EBioMedicine, 2020, 61, 103059.	2.7	28
510	Facing life-prolonging treatment: The perspectives of men with advanced metastatic prostate cancer â€“ An interview study. European Journal of Oncology Nursing, 2020, 49, 101859.	0.9	6
511	Resetting the Bar of Castration Resistance â€“ Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 199-207.	0.9	7
512	Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. Anti-Cancer Drugs, 2020, 31, 1099-1102.	0.7	1
513	Current status of PSMA PET imaging in prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 7-11.	0.7	3
514	Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review. Cancer Cell International, 2020, 20, 409.	1.8	21
515	Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. Diagnostics, 2020, 10, 658.	1.3	7
517	Singleâ€fraction imageâ€guided robotic radiosurgery efficiently controls local prostate cancer recurrence after radical prostatectomy. BJUI Compass, 2020, 1, 139-145.	0.7	3
518	How to deal with steroids use in the management of metastatic prostate cancer during pandemic. Translational Andrology and Urology, 2020, 9, 1546-1549.	0.6	0
519	Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence. Current Opinion in Urology, 2020, Publish Ahead of Print, 635-640.	0.9	3
520	Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy. Cancers, 2020, 12, 2271.	1.7	18
521	The potential of PSMA-targeted alpha therapy in the management of prostate cancer. Expert Review of Anticancer Therapy, 2020, 20, 823-829.	1.1	30

#	Article	IF	Citations
522	Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models. Clinical Cancer Research, 2020, 26, 6387-6398.	3.2	36
523	Bone scan use in the management of metastatic castration-resistant prostate cancer: Survey of practice patterns among Canadian radiation oncologists, medical oncologists, and urologists. Canadian Urological Association Journal, 2020, 14, E601-E603.	0.3	0
524	Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer, 2020, 20, 884.	1.1	32
526	Clinical impact of PSMA PET in biochemically recurrent prostate cancer; aÂreview of the literature. Tijdschrift Voor Urologie, 2020, 10, 109-121.	0.1	12
527	Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level â‰¥0.5â€‰ng/mL. Nuclear Medicine Communications, 2020, 41, 906-915.	0.5	9
528	AKR1C3 mediates panâ€AR antagonist resistance in castrationâ€resistant prostate cancer. Prostate, 2020, 80, 1223-1232.	1.2	3
529	Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 562504.	1.3	10
530	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. Molecules, 2020, 25, 5993.	1.7	6
531	MR-Guided Radiotherapy for Prostate Cancer. Frontiers in Oncology, 2020, 10, 616291.	1.3	58
532	Salvage Magnetic Resonance Imagingâ€“guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results. European Urology Open Science, 2020, 22, 79-87.	0.2	16
533	Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study. Frontiers in Oncology, 2020, 10, 527952.	1.3	6
534	Polypeptide-Based Molecular Platform and Its Docetaxel/Sulfo-Cy5-Containing Conjugate for Targeted Delivery to Prostate Specific Membrane Antigen. Molecules, 2020, 25, 5784.	1.7	13
535	Salvage Pelvic Lymph Node Dissection and Current State of Imaging for Recurrent Prostate Cancer: Does a Standard Exist?. Current Urology Reports, 2020, 21, 62.	1.0	2
536	Systemic effects of the hormonal treatment of male hypogonadism with preliminary indications for the management of COVID-19 patients. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882096643.	1.4	6
537	Harnessing the potential of multimodal radiotherapy in prostate cancer. Nature Reviews Urology, 2020, 17, 321-338.	1.9	15
538	Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clinical Nuclear Medicine, 2020, 45, 349-355.	0.7	7
539	The near-infrared fluorescent dye IR-780 was coupled with cabazitaxel for castration-resistant prostate cancer imaging and therapy. Investigational New Drugs, 2020, 38, 1641-1652.	1.2	3
540	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus, 2021, 7, 788-796.	1.6	1

#	Article	IF	Citations
541	Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2020, 12, 1078.	1.7	16
542	Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. Strahlentherapie Und Onkologie, 2020, 196, 1006-1017.	1.0	8
543	Impact of ⁶⁸Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine, 2020, 61, 1793-1799.	2.8	74
544	Challenges, applications and future directions of precision medicine in prostate cancer â€“ the role of organoids and patientâ€derived xenografts. BJU International, 2020, 126, 65-72.	1.3	9
545	Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 795.e1-795.e8.	0.8	17
546	Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer â€“5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. Clinical Oncology, 2020, 32, e177-e187.	0.6	11
547	Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 682.e1-682.e9.	0.8	8
548	Increased expression of microRNA-93 correlates with progression and prognosis of prostate cancer. Medicine (United States), 2020, 99, e18432.	0.4	9
549	Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2020, 25, 1695-1703.	1.0	3
550	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncology, 2020, 16, 1371-1384.	1.1	25
551	Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. New England Journal of Medicine, 2020, 382, 2187-2196.	13.9	259
552	The role of taxane-based chemotherapy in the treatment of prostate cancer. Current Opinion in Urology, 2020, 30, 527-533.	0.9	5
553	Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 629-638.	1.1	4
554	Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives. International Journal of Molecular Sciences, 2020, 21, 3690.	1.8	10
555	Early salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: Its impact and optimal candidate. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 273-279.	0.7	3
556	Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management. American Journal of Roentgenology, 2020, 215, 267-276.	1.0	9
557	A clinicianâ€™s guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2067-2075.	1.2	5
558	Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy. BMC Urology, 2020, 20, 71.	0.6	4

#	Article	IF	Citations
559	Prostate cancer: more effective use of underutilized postoperative radiation therapy. Expert Review of Anticancer Therapy, 2020, 20, 241-249.	1.1	1
560	Lâ€™adÃ©nocarcinome prostatique, premier cancer chez lâ€™homme Ã¢gÃ© enÂFrance. Actualites Pharmaceutiques, 2020, 59, 29-33.	0.0	0
561	Radium-223 as an Approved Modality for Treatment of Bone Metastases. Seminars in Nuclear Medicine, 2020, 50, 177-192.	2.5	28
562	Preliminary results of targeted prostateâ€specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castrationâ€resistant prostate cancer. Cancer Medicine, 2020, 9, 3278-3286.	1.3	3
563	Development of a multivariable risk model integrating urinary cell DNA methylation and cellâ€free RNA data for the detection of significant prostate cancer. Prostate, 2020, 80, 547-558.	1.2	17
564	Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. BMC Medical Imaging, 2020, 20, 25.	1.4	10
565	Solitary prostate cancer liver metastasis: an exceptional indication for liver resection. Acta Chirurgica Belgica, 2020, 121, 1-5.	0.2	2
566	Radiomics prediction model for the improved diagnosis of clinically significant prostate cancer on biparametric MRI. Quantitative Imaging in Medicine and Surgery, 2020, 10, 368-379.	1.1	40
567	Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse. Scientific Reports, 2020, 10, 4993.	1.6	9
568	Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review. Radiographics, 2020, 40, 709-726.	1.4	33
569	Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCÎµ/PKCÎµ Signaling Pathway. Frontiers in Oncology, 2020, 10, 75.	1.3	1
570	18F-choline PET/CT driven salvage radiotherapy in prostate cancer patients: up-date analysis with 5-year median follow-up. Radiologia Medica, 2020, 125, 668-673.	4.7	6
571	Upâ€regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence. Journal of Cellular and Molecular Medicine, 2020, 24, 4698-4706.	1.6	16
572	Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998â€“2016. Acta OncolÃ³gica, 2020, 59, 549-557.	0.8	11
573	Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. International Journal of Biological Sciences, 2020, 16, 1121-1134.	2.6	98
574	Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate, 2020, 80, 527-544.	1.2	34
575	Deep convolutional neural networks combine Raman spectral signature of serum for prostate cancer bone metastases screening. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102245.	1.7	29
576	Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study. European Radiology, 2020, 30, 6042-6051.	2.3	20

#	Article	IF	Citations
577	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 1119-1134.	0.6	485
578	Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. Nature Reviews Urology, 2020, 17, 469-481.	1.9	29
579	Can the combination of biparametric magnetic resonance imaging and PSAâ€related indicators predict the prostate biopsy outcome?. Andrologia, 2020, 52, e13734.	1.0	1
580	Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). Strahlentherapie Und Onkologie, 2020, 196, 1034-1043.	1.0	29
581	Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3293-e3299.	1.8	47
582	Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen Therapy. Cancers, 2020, 12, 1716.	1.7	17
583	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 4795-4804.	3.2	58
584	The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials, 2020, 21, 579.	0.7	16
585	Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2020, 44, 156-163.	0.2	0
586	68Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis. European Journal of Radiology, 2020, 130, 109131.	1.2	15
587	A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis. Advances in Radiation Oncology, 2020, 5, 965-977.	0.6	29
588	Sexual Motivators and Endorsement of Models Describing Sexual Response of Men Undergoing Androgen Deprivation Therapy for Advanced Prostate Cancer. Journal of Sexual Medicine, 2020, 17, 1538-1543.	0.3	9
589	Salvage Radiotherapy for Prostate Cancer. Clinical Oncology, 2020, 32, 156-162.	0.6	13
590	Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer and Prostatic Diseases, 2020, 23, 220-231.	2.0	39
591	miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression. Cells, 2020, 9, 435.	1.8	11
592	Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy. European Urology Oncology, 2021, 4, 821-825.	2.6	42
593	Prostate Cancer Nodal Staging: Using Deep Learning to Predict 68Ga-PSMA-Positivity from CT Imaging Alone. Scientific Reports, 2020, 10, 3398.	1.6	33
594	Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy. Aging Male, 2020, 23, 1210-1216.	0.9	3

#	Article	IF	Citations
595	The Relationship Between Total Lesion Activity on 18F Choline Positron Emission Tomography-Computed Tomography and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Bone Metastases Treated with 223Radium. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 398-403.	0.7	6
596	Novel patient-derived 3D culture models to guide clinical decision-making in prostate cancer. Current Opinion in Endocrine and Metabolic Research, 2020, 10, 7-15.	0.6	6
597	68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patientsâ€™ disease management and adequacy of impact. Scientific Reports, 2020, 10, 2104.	1.6	33
598	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 148, 102861.	2.0	29
599	Impact of advanced radiotherapy techniques and dose intensification on toxicity of salvage radiotherapy after radical prostatectomy. Scientific Reports, 2020, 10, 114.	1.6	14
600	Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. Scientific Reports, 2020, 10, 227.	1.6	42
601	Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. PLoS ONE, 2020, 15, e0228447.	1.1	23
602	Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 129-136.	0.8	24
603	A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. Cancers, 2020, 12, 132.	1.7	7
604	AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC. Urologia Internationalis, 2020, 104, 253-262.	0.6	4
605	Role of Para-aortic Radiotherapy in the Management of Prostate Cancer. Clinical Oncology, 2020, 32, 189-198.	0.6	10
606	Expanding the role of small-molecule PSMA ligands beyond PET staging ofÂprostate cancer. Nature Reviews Urology, 2020, 17, 107-118.	1.9	41
607	Indications and outcome in surgically treated asymptomatic meningiomas: a single-center case-control study. Acta Neurochirurgica, 2020, 162, 2155-2163.	0.9	21
608	Sight and switch off: Nerve density visualization for interventions targeting nerves in prostate cancer. Science Advances, 2020, 6, eaax6040.	4.7	28
609	Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Cancer Research, 2020, 80, 2927-2939.	0.4	13
610	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	1.1	20
611	Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer. BMC Cancer, 2020, 20, 361.	1.1	28
613	NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway. Experimental Cell Research, 2020, 390, 111981.	1.2	14

#	Article	IF	Citations
614	Prognostic value of seminal vesicle invasion on preoperative multi-parametric magnetic resonance imaging in pathological stage T3b prostate cancer. Scientific Reports, 2020, 10, 5693.	1.6	12
615	Does Gleason score of positive surgical margin after radical prostatectomy affect biochemical recurrence and oncological outcomes? Protocol for systematic review. BMJ Open, 2020, 10, e034612.	0.8	2
616	Harnessing the patient voice in prostate cancer research: Systematic review on the use of patientâ€reported outcomes in randomized controlled trials to support clinical decisionâ€making. Cancer Medicine, 2020, 9, 4039-4058.	1.3	11
617	Pelvic exenteration surgery in patients with locally advanced castrationâ€naÃ¯ve and castrationâ€resistant, symptomatic prostate cancer. BJU International, 2020, 126, 342-349.	1.3	8
618	68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2804-2815.	3.3	27
619	Safety and Feasibility of Radiation Therapy to the Primary Tumor in Patients With Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e523-e530.	0.9	3
620	Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. Medicine (United States), 2020, 99, e19760.	0.4	34
621	Applied anatomy of pelvic lymph nodes and its clinical significance for prostate cancer:a single-center cadaveric study. BMC Cancer, 2020, 20, 330.	1.1	6
622	Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model. Canadian Urological Association Journal, 2020, 14, E418-E427.	0.3	4
623	Early experience with Watson for Oncology: a clinical decision-support system for prostate cancer treatment recommendations. World Journal of Urology, 2021, 39, 407-413.	1.2	19
624	Candidates to salvage therapy after external-beam radiotherapy of prostate cancer: Predictors of local recurrence volume and metastasis-free survival. Diagnostic and Interventional Imaging, 2021, 102, 93-100.	1.8	2
625	Anti-tumor activities of Panax quinquefolius saponins and potential biomarkers in prostate cancer. Journal of Ginseng Research, 2021, 45, 273-286.	3.0	10
626	Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer. Radiotherapy and Oncology, 2021, 154, 255-259.	0.3	6
627	Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1243-1253.	0.4	35
628	Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 509-520.	3.3	60
629	18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 521-531.	3.3	16
630	Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist. Prostate Cancer and Prostatic Diseases, 2021, 24, 177-185.	2.0	11
631	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€"2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 2021, 79, 263-282.	0.9	633

#	Article	IF	Citations
632	Impact of 68 Gallium prostateâ€specific membrane antigen tracers on the management of patients with prostate cancer who experience biochemical recurrence. BJU International, 2021, 127, 153-163.	1.3	6
633	Androgen receptor signalingâ€targeted therapy and taxane chemotherapy induce visceral metastasis in castrationâ€resistant prostate cancer. Prostate, 2021, 81, 72-80.	1.2	15
634	Management of newly diagnosed metastatic hormoneâ€sensitive prostate cancer: A survey of UK Uroâ€oncologists. International Journal of Clinical Practice, 2021, 75, e13874.	0.8	0
635	The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Critical Reviews in Oncology/Hematology, 2021, 157, 103199.	2.0	16
636	The Nexus of Endocrine Signaling and Cancer: How Steroid Hormones Influence Genomic Stability. Endocrinology, 2021, 162, .	1.4	14
637	Impact of Radiotherapy on Prognosis in Patients Diagnosed with Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis. Urologia Internationalis, 2021, 105, 370-379.	0.6	1
638	Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer and Prostatic Diseases, 2021, 24, 514-523.	2.0	10
639	Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report. Current Problems in Cancer Case Reports, 2021, 3, 100038.	0.1	2
640	The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 296.e11-296.e19.	0.8	6
641	Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). Prostate Cancer and Prostatic Diseases, 2021, 24, 439-447.	2.0	0
642	Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 130.e1-130.e7.	0.8	0
643	Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. Urologia Internationalis, 2021, 105, 380-385.	0.6	2
644	Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014â€“2018 French Population Study (the SPEAR Cohort). American Journal of Epidemiology, 2021, 190, 413-422.	1.6	16
645	Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer and Prostatic Diseases, 2021, 24, 341-348.	2.0	8
646	Surveillance of Clinically Complete Responders Using Serial ¹⁸F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy. Journal of Nuclear Medicine, 2021, 62, 486-492.	2.8	11
647	Prostate-specific Membrane Antigen Positron Emission Tomographyâ€“detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	1.6	34
648	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. European Urology Oncology, 2021, 4, 66-72.	2.6	20
649	Grade group 2 (10%â€‰â‰¥â€‰GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate. International Journal of Clinical Oncology, 2021, 26, 764-769.	1.0	5

#	Article	IF	Citations
650	Impact of PSMA PET on management of biochemical recurrent prostate cancer: a systematic review and meta-analysis of prospective studies. Clinical and Translational Imaging, 2021, 9, 95-108.	1.1	4
651	Oncological Long-term Outcome After Whole-gland High-intensity Focused Ultrasound for Prostate Cancerâ€"21-yr Follow-up. European Urology Focus, 2022, 8, 134-140.	1.6	10
652	Unusual uptakes on 18F-fluorocholine positron emission tomography/computed tomography (PET/CT): a retrospective study of 368 prostate cancer patients referred for a biochemical recurrence or an initial staging. Quantitative Imaging in Medicine and Surgery, 2021, 11, 172-182.	1.1	11
653	The efficiency of prostate-specific antigen density measurement using three different methods on the prediction of biochemical recurrence. Aging Male, 2021, 24, 15-23.	0.9	2
654	Particle Swarm Optimized Gaussian Process Classifier for Treatment Discontinuation Prediction in Multicohort Metastatic Castration-Resistant Prostate Cancer Patients. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 1309-1317.	3.9	1
655	IL-4 Counteracts the Cytotoxic Effects of Peripheral Blood Mononuclear Cells on Hormone-sensitive Prostate Cancer Cells. In Vivo, 2021, 35, 1973-1977.	0.6	1
656	New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. Cells, 2021, 10, 193.	1.8	26
657	[18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1773-1784.	3.3	2
658	Long Noncoding RNAs as Innovative Urinary Diagnostic Biomarkers. Methods in Molecular Biology, 2021, 2292, 73-94.	0.4	4
659	Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer. Prostate, 2021, 81, 223-230.	1.2	6
660	A Novel Set of Immune-associated Gene Signature predicts Biochemical Recurrence in Localized Prostate Cancer Patients after Radical Prostatectomy. Journal of Cancer, 2021, 12, 3715-3725.	1.2	8
661	Targeted micelles with chemotherapeutics and gene drugs to inhibit the G1/S and G2/M mitotic cycle of prostate cancer. Journal of Nanobiotechnology, 2021, 19, 17.	4.2	26
662	Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxelâ€sensitive and docetaxelâ€resistant castrationâ€resistant prostate cancer cells. Journal of Cellular and Molecular Medicine, 2021, 25, 2436-2449.	1.6	17
663	The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression. Cancer Cell International, 2021, 21, 45.	1.8	9
664	Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer. Communications Biology, 2021, 4, 119.	2.0	18
665	Genome-wide Expression Analysis Identifies the Association between SEC14L2 and Castration-resistant Prostate Cancer Survival. Journal of Cancer, 2021, 12, 2173-2180.	1.2	1
666	Long-Lasting Palliation of Bone Oligometastatic Prostate Cancer After Repeated Stereotactic Body Radiotherapy. Ochsner Journal, 2021, 21, 301-305.	0.5	0
667	Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1. International Journal of Nanomedicine, 2021, Volume 16, 315-327.	3.3	15

#	Article	IF	Citations
668	Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy. Frontiers in Oncology, 2020, 10, 606260.	1.3	3
669	Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?. World Journal of Urology, 2021, 39, 3231-3237.	1.2	5
670	Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy: a case report. International Cancer Conference Journal, 2021, 10, 96-99.	0.2	1
671	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060.	3.2	13
672	[18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA <â€‰0.5Âng/mL. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2038-2046.	3.3	22
673	68Ga-PSMA ligand PET/CT integrating indocyanine green-guided salvage lymph node dissection for lymph node metastasis after radical prostatectomy. Asian Journal of Andrology, 2021, .	0.8	1
674	Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients. European Radiology, 2021, 31, 4595-4605.	2.3	54
675	Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer. Asian Journal of Andrology, 2022, 24, 50.	0.8	2
676	Sequential Docetaxel in â‰¥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. Scientific World Journal, The, 2021, 2021, 1-9.	0.8	1
677	Dual-phase 68Ga-PSMA-11 PET/CT may increase the rate of detected lesions in prostate cancer patients. Urologia, 2021, 88, 039156032199354.	0.3	3
678	Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3315-3324.	3.3	47
679	A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 465-477.	0.8	1
680	CÃ¡ncer de prÃ³stata. Medicine, 2021, 13, 1454-1466.	0.0	0
681	Nomogram predicting survival to assist decision-making of radical prostatectomy in patients with metastatic prostate cancer. Translational Andrology and Urology, 2021, 10, 879-887.	0.6	3
682	Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2021, 24, 612-622.	2.0	6
683	Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis. Cancers, 2021, 13, 882.	1.7	35
684	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
685	PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castrationâ€resistance prostate cancer patients treated with docetaxel. Andrologia, 2021, 53, e13916.	1.0	2

#	Article	IF	Citations
686	Identification and validation of a six immune-related gene signature for prediction of biochemical recurrence in localized prostate cancer following radical prostatectomy. Translational Andrology and Urology, 2021, 10, 1018-1029.	0.6	6
687	Radium-223 in the Modern Treatment of Metastatic Castration-resistant Prostate Cancer. Health of Man, 2020, , 71-75.	0.1	0
688	Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy. International Journal of Urology, 2021, 28, 566-572.	0.5	14
689	Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. Turkish Journal of Urology, 2021, 47, 120-124.	1.3	1
690	Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3683-3692.	3.3	21
691	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.3	3
692	Tumor Detection of ¹⁸F-PSMA-1007 in the Prostate Gland in Patients with Prostate Cancer Using Prostatectomy Specimens as Reference Method. Journal of Nuclear Medicine, 2021, 62, 1735-1740.	2.8	10
693	Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer. Frontiers in Surgery, 2021, 8, 637134.	0.6	0
694	Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiation Oncology, 2021, 16, 50.	1.2	37
695	How I Treat Metastatic Hormone-Sensitive Prostate Cancer?. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 100-107.	0.1	0
696	Oligometastatic prostatic cancer recurrence: role of salvage lymph node dissection (sLND) and radiation therapy-stereotactic body radiation therapy (RT-SBRT). Current Opinion in Urology, 2021, 31, 199-205.	0.9	2
697	Tissue N-linked glycosylation as potential prognostic biomarker for biochemical recurrence-free survival. Biomarkers, 2021, 26, 275-285.	0.9	2
698	Analysis of Brain Functions in Men with Prostate Cancer under Androgen Deprivation Therapy: A One-Year Longitudinal Study. Life, 2021, 11, 227.	1.1	9
699	Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3325-3334.	3.3	15
700	Herb-target virtual screening and network pharmacology for prediction of molecular mechanism of Danggui Beimu Kushen Wan for prostate cancer. Scientific Reports, 2021, 11, 6656.	1.6	18
701	Detection Efficacy of ¹⁸Fâ€ŕhPSMAâ€7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment. Journal of Nuclear Medicine, 2021, 62, 1719-1726.	2.8	14
702	Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: a population-based cohort study. Prostate Cancer and Prostatic Diseases, 2021, 24, 1055-1062.	2.0	4
703	Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study. Prostate Cancer and Prostatic Diseases, 2021, 24, 852-859.	2.0	11

#	Article	IF	Citations
704	Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Targeted Oncology, 2021, 16, 369-380.	1.7	21
705	Restaging the Biochemical Recurrence of Prostate Cancer with [68Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management. Cancers, 2021, 13, 1594.	1.7	10
706	Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in firstâ€line treatment of metastatic castrationâ€resistant prostate cancer. Cancer Medicine, 2021, 10, 2332-2340.	1.3	24
707	Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy. Cancers, 2021, 13, 2102.	1.7	5
708	177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. Biomedicines, 2021, 9, 430.	1.4	13
709	Pulmonary metastasectomy in germ cell tumors and prostate cancer. Journal of Thoracic Disease, 2021, 13, 2661-2668.	0.6	3
710	Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. EJNMMI Research, 2021, 11, 41.	1.1	12
711	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clinical Cancer Research, 2021, 27, 3595-3601.	3.2	53
712	Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the JMJD6 Regulon in Clinical Prostate Cancer. Cancers, 2021, 13, 2094.	1.7	6
713	Application of metastatic biopsy based on â€œWhen, Who, Why, Where, How (4W1H)â€•principle in diagnosis and treatment of metastatic castration-resistance prostate cancer. Translational Andrology and Urology, 2021, 10, 1723-1733.	0.6	2
714	Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). JCO Global Oncology, 2021, 7, 559-571.	0.8	10
715	Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 664225.	1.3	7
716	Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. Diagnostics, 2021, 11, 665.	1.3	6
717	What are effective treatments for advanced castration-resistant prostate cancer marked by rapidly rising PSA?. Evidence-Based Practice, 2021, Publish Ahead of Print, .	0.0	0
718	Radiotherapy in nodal oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 575-580.	1.0	11
719	Male sexual dysfunction and rehabilitation strategies in the settings of salvage prostate cancer treatment. International Journal of Impotence Research, 2021, 33, 457-463.	1.0	10
720	The Use of Upconversion Nanoparticles in Prostate Cancer Photodynamic Therapy. Life, 2021, 11, 360.	1.1	16
721	Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3723-3731.	3.3	10

#	Article	IF	Citations
722	The Effect of Local Therapy on M1c Prostate Cancer Patients: A Systematic Review and Meta-Analysis. Frontiers in Surgery, 2021, 8, 648676.	0.6	0
723	Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy. Frontiers in Oncology, 2021, 11, 669261.	1.3	8
724	Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?. Clinical Genitourinary Cancer, 2021, , .	0.9	0
725	Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride. Scientific Reports, 2021, 11, 7389.	1.6	7
726	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 640467.	1.3	11
727	225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient. Acta Radiologica Open, 2021, 10, 205846012110225.	0.3	0
728	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Medical Oncology, 2021, 38, 72.	1.2	6
730	Serum testosterone levels and testosterone â€˜bounceâ€™ phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 829.e9-829.e17.	0.8	2
731	Identification and Validation of a Prognostic 5-Protein Signature for Biochemical Recurrence Following Radical Prostatectomy for Prostate Cancer. Frontiers in Surgery, 2021, 8, 665115.	0.6	1
732	2020 Korean guidelines for the management of metastatic prostate cancer. Korean Journal of Internal Medicine, 2021, 36, 491-514.	0.7	5
733	A retrospective study assessing the accuracy of [18F]â€“fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection. Scandinavian Journal of Urology, 2021, 55, 293-297.	0.6	3
734	The one hundred most cited publications in prostate brachytherapy. Brachytherapy, 2021, 20, 611-623.	0.2	1
736	Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder. Molecular Oncology, 2021, 15, 1882-1900.	2.1	5
737	Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study. Japanese Journal of Clinical Oncology, 2021, 51, 1452-1461.	0.6	3
738	Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. World Journal of Urology, 2021, 39, 3789-3797.	1.2	14
739	Validation of the European association of urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 298.e1-298.e6.	0.8	6
740	Primary Gleason grade and Gleason grade group at positive surgical margins: a systematic review and metaâ€anâ€alysis. BJU International, 2021, 127, 13-22.	1.3	11
741	The discovery of novel sanjuanolide derivatives as chemotherapeutic agents targeting castration-resistant prostate cancer. Bioorganic Chemistry, 2021, 111, 104880.	2.0	1

#	Article	IF	Citations
742	68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. World Journal of Urology, 2021, 39, 4117-4125.	1.2	1
743	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Communications Biology, 2021, 4, 670.	2.0	50
744	Functionalized Selenium Nanotherapeutics Synergizes With Zoledronic Acid to Suppress Prostate Cancer Cell Growth Through Induction of Mitochondria-Mediated Apoptosis and Cell Cycle S Phase Arrest. Frontiers in Oncology, 2021, 11, 685784.	1.3	9
745	Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy. Frontiers in Oncology, 2021, 11, 665304.	1.3	7
746	68 Gaâ€prostateâ€specific membrane antigen (PSMA) PET/CT as a clinical decisionâ€making tool in biochemically recurrent prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	0
747	Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study. Clinical Genitourinary Cancer, 2021, 19, e171-e177.	0.9	0
748	Epigenetic Editing in Prostate Cancer: Challenges and Opportunities. Epigenetics, 2022, 17, 564-588.	1.3	4
749	TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 368.e1-368.e9.	0.8	6
750	MR compatibility, safety and accuracy of the redesigned UMC Utrecht single needle implant device. Physics in Medicine and Biology, 2021, 66, 12NT02.	1.6	0
752	Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiation Oncology, 2021, 16, 125.	1.2	17
753	68Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer. Annals of Nuclear Medicine, 2021, 35, 1109-1116.	1.2	8
754	Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review. Translational Andrology and Urology, 2021, 10, 3167-3175.	0.6	9
755	Androgen receptor expression in breast cancer: Implications on prognosis and treatment, a brief review. Molecular and Cellular Endocrinology, 2021, 531, 111324.	1.6	13
756	Prostate Cancer Theranostics. PET Clinics, 2021, 16, 391-396.	1.5	11
757	Real-world incidence of symptomatic skeletal events and bone-modifying agentÂuse in castration-resistant prostate cancer â€“ an Australian multi-centre observational study. European Journal of Cancer, 2021, 157, 485-492.	1.3	7
758	Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. Pharmaceuticals, 2021, 14, 670.	1.7	11
759	Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. Current Oncology, 2021, 28, 2881-2892.	0.9	16
760	An overview of the latest in state-of-the-art murine models for prostate cancer. Expert Opinion on Drug Discovery, 2021, 16, 1349-1364.	2.5	3

#	Article	IF	Citations
761	Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 460-469.	3.3	36
762	Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience. Nuclear Medicine Communications, 2021, 42, 1254-1260.	0.5	7
763	Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Network Open, 2021, 4, e2116536.	2.8	11
764	Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer. Frontiers in Oncology, 2021, 11, 715020.	1.3	9
765	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 71-78.	2.0	19
766	HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate Cancer. Biomedicines, 2021, 9, 893.	1.4	2
767	Clinicopathological Analysis of the ISUP Grade Group And Other Parameters in Prostate Cancer: Elucidation of Mutual Impact of the Various Parameters. Frontiers in Oncology, 2021, 11, 695251.	1.3	7
768	Comparing the risk of cardiovascular disease following GnRH agonist and GnRH antagonist therapy for patient with prostate cancer: a systematic review and meta-analysis. Minerva Urology and Nephrology, 2021, 73, 276-282.	1.3	5
769	Gonadotropinâ€releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropinâ€releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study. Prostate, 2021, 81, 902-912.	1.2	10
771	Salvage therapy for prostate cancer after radical prostatectomy. Nature Reviews Urology, 2021, 18, 643-668.	1.9	26
772	Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275). Clinical and Experimental Metastasis, 2021, 38, 451-458.	1.7	4
773	Impact of early hypothalamic-pituitary-gonadal axis maturation on prostate cancer: cross-sectional analysis of a Veterans affairs cohort. Translational Andrology and Urology, 2021, 10, 3368-3374.	0.6	0
774	High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry. Journal of Palliative Medicine, 2021, 24, 1789-1797.	0.6	4
775	Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis. Supportive Care in Cancer, 2022, 30, 855-863.	1.0	2
776	Gene signatures predict biochemical recurrenceâ€free survival in primary prostate cancer patients after radical therapy. Cancer Medicine, 2021, 10, 6492-6502.	1.3	7
778	Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory <scp>T</scp> cells and macrophages as adverse prognostic factors. Journal of Pathology, 2021, 255, 155-165.	2.1	36
779	Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer. European Radiology, 2022, 32, 901-911.	2.3	11
780	Making Radiomics More Reproducible across Scanner and Imaging Protocol Variations: A Review of Harmonization Methods. Journal of Personalized Medicine, 2021, 11, 842.	1.1	72

#	Article	IF	Citations
781	Salvage local treatment for localized radio-recurrent prostate cancer: a narrative review and future perspectives. Future Oncology, 2021, 17, 4207-4219.	1.1	0
782	Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis. Clinical Genitourinary Cancer, 2021, 19, e223-e234.	0.9	1
783	Current usage of stereotactic body radiotherapy for oligometastatic prostate cancer in Korea: patterns of care survey (KROG 19-08). Annals of Translational Medicine, 2021, 9, 1291-1291.	0.7	3
784	Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU International, 2022, 129, 699-707.	1.3	19
785	Presence of corpora amylacea among prostate cancer cells: an unrecognised feature of intraductal carcinoma of the prostate. Pathology, 2021, 53, 574-578.	0.3	0
786	KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Future Oncology, 2021, 17, 3017-3026.	1.1	19
787	Novel immuneâ€related signature for risk stratification and prognosis in prostatic adenocarcinoma. Cancer Science, 2021, 112, 4365-4376.	1.7	11
788	Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET. Clinical Genitourinary Cancer, 2021, 19, 346-353.	0.9	1
789	Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. Cancer Management and Research, 2021, Volume 13, 7009-7031.	0.9	0
790	Pathological significance and prognostic role of LATS2 in prostate cancer. Prostate, 2021, 81, 1252-1260.	1.2	2
791	Predictive factors of survival outcomes in firstâ€line therapy for metastatic castrationâ€resistant prostate cancer. International Journal of Urology, 2022, 29, 26-32.	0.5	5
792	Differences in sex hormone recovery profile after cessation of 12â€week gonadotropinâ€releasing hormone antagonist versus agonist therapy. Andrology, 2021, , .	1.9	2
793	Improvement in overall and cancerâ€specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. Prostate, 2021, 81, 1374-1381.	1.2	8
794	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncology, 2021, 17, 3291-3299.	1.1	22
795	Extended robotâ€assisted laparoscopic prostatectomy and extended pelvic lymph node dissection as a monotherapy in patients with very highâ€risk prostate cancer Patients. Cancer Medicine, 2021, 10, 7968-7976.	1.3	3
796	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	0.9	49
797	Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 695136.	1.3	6
798	Adaptive magnetic resonance-guided neurovascular-sparing radiotherapy for preservation of erectile function in prostate cancer patients. Physics and Imaging in Radiation Oncology, 2021, 20, 5-10.	1.2	15

#	Article	IF	Citations
799	Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications. Clinica Chimica Acta, 2021, 521, 70-75.	0.5	8
800	A decade of multi-modality PET and MR imaging in abdominal oncology. British Journal of Radiology, 2021, 94, 20201351.	1.0	0
801	Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center. European Urology, 2021, 80, 489-496.	0.9	9
802	Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation. Clinical and Translational Radiation Oncology, 2021, 31, 21-27.	0.9	0
803	PSMA-targeted low-molecular double conjugates for diagnostics and therapy. European Journal of Medicinal Chemistry, 2021, 225, 113752.	2.6	8
804	Molecular Detection of Human Herpes Virus-8 in Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia Tissues by DNA -In Situ Hybridization. Iraqi Journal of Science, 0, , 96-107.	0.3	0
805	The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing. Frontiers in Cell and Developmental Biology, 2020, 8, 602493.	1.8	31
806	Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment. BioMed Research International, 2021, 2021, 1-11.	0.9	10
807	Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naÃ¯ve metastatic prostate cancer: a multi-institutional comparative analysis. Translational Andrology and Urology, 2021, 10, 417-425.	0.6	4
808	Seizures and Neuropsychiatric Toxicity in Patients with Non-Metastatic CRPC Treated with New Antiandrogens: Systematic Review and Meta-Analysis. Oncology Research and Treatment, 2021, 44, 154-163.	0.8	1
809	Hormonal Therapy for Prostate Cancer. Endocrine Reviews, 2021, 42, 354-373.	8.9	136
810	Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial. World Journal of Urology, 2021, 39, 357-364.	1.2	2
811	Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World Journal of Urology, 2021, 39, 307-315.	1.2	33
812	68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?. Wiener Medizinische Wochenschrift, 2019, 169, 3-11.	0.5	14
813	Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery. European Urology Focus, 2019, 5, 50-53.	1.6	52
814	Techniques and Outcomes of Salvage Robot-Assisted Radical Prostatectomy (sRARP). European Urology, 2020, 78, 885-892.	0.9	19
815	The Impact of Positron Emission Tomography with ¹⁸ F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. Journal of Urology, 2019, 201, 322-331.	0.2	113
817	Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress. Cell Cycle, 2020, 19, 541-550.	1.3	5

#	Article	IF	Citations
818	Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy. Clinical Nuclear Medicine, 2020, 45, 935-942.	0.7	33
819	99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2021, 46, e68-e74.	0.7	31
820	18F-Fluciclovine PET/CT in Therapeutic Decision Making for Prostate Cancer. Clinical Nuclear Medicine, 2021, 46, 187-194.	0.7	9
821	Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial. BMC Cancer, 2020, 20, 457.	1.1	7
822	Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. EJNMMI Research, 2020, 10, 52.	1.1	16
823	Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer. EJNMMI Research, 2020, 10, 17.	1.1	20
824	Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer. EJNMMI Physics, 2020, 7, 31.	1.3	17
825	Phospholipase C (PLC)Îμ Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line. Medical Science Monitor, 2019, 25, 4438-4449.	0.5	6
826	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. PLoS ONE, 2020, 15, e0239414.	1.1	6
827	Prognostic value of microRNA-20b expression level in patients with prostate cancer. Histology and Histopathology, 2020, 35, 827-831.	0.5	4
828	Anti-cancer effect of GV1001 for prostate cancer: function as a ligand of GnRHR. Endocrine-Related Cancer, 2019, 26, 147-162.	1.6	9
829	Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 891-902.	0.7	7
830	Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget, 2017, 8, 55567-55574.	0.8	59
831	Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium. Oncotarget, 2017, 8, 49264-49274.	0.8	5
832	Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. Oncotarget, 2017, 8, 59165-59180.	0.8	15
833	Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget, 2017, 8, 84180-84192.	0.8	41
834	Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. Oncotarget, 2017, 8, 103108-103116.	0.8	67
835	The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Oncotarget, 2019, 10, 6124-6137.	0.8	15

#	Article	IF	Citations
836	Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 511-520.	0.7	7
837	Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis . Therapeutics and Clinical Risk Management, 2020, Volume 16, 393-401.	0.9	31
838	Transdermal Delivery of Luteinizing Hormone-releasing Hormone with Chitosan Microneedles: A Promising Tool for Androgen Deprivation Therapy. Anticancer Research, 2017, 37, 6791-6797.	0.5	11
839	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. JMIR Research Protocols, 2018, 7, e11256.	0.5	12
840	Oligometastatic prostate cancer and salvage lymph node dissection: systematic review. Minerva Chirurgica, 2019, 74, 97-106.	0.8	5
841	A systematic review of imaging-guided metastasis-directed therapy for oligorecurrent prostate cancer: revolution or devolution?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 279-291.	3.9	5
842	The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 170-182.	0.4	7
843	Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 66, .	0.4	18
844	The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 48-54.	2.8	15
845	The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. Journal of Nuclear Medicine, 2020, 61, 263S-272S.	2.8	67
846	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. Ecancermedicalscience, 2020, 14, 1036.	0.6	5
847	Imaging for Metastasis in Prostate Cancer: A Review of the Literature. Frontiers in Oncology, 2020, 10, 55.	1.3	46
848	PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer. Cancers, 2020, 12, 398.	1.7	17
849	Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. Cancers, 2020, 12, 1278.	1.7	45
850	Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells inï¿½vitro. Experimental and Therapeutic Medicine, 2020, 19, 755-761.	0.8	11
851	Assessment of biochemical recurrence of prostate cancer (Review). International Journal of Oncology, 2019, 55, 1194-1212.	1.4	14
852	Moderne behandling av prostatakreft med fjernmetastaser. Tidsskrift for Den Norske Laegeforening, 2017, 137, 803-805.	0.2	11
853	PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Asian Journal of Andrology, 2018, 20, 173.	0.8	5

#	Article	IF	Citations
854	Role of tumor-associated immune cells in prostate cancer: angel or devil?. Asian Journal of Andrology, 2019, 21, 433.	0.8	16
855	Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study. Asian Journal of Andrology, 2018, 20, 545.	0.8	7
856	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. Asian Journal of Andrology, 2019, 21, 12.	0.8	5
857	Clinical and oncologic findings of extraprostatic extension on needle biopsy in de novo metastatic prostate cancer. Asian Journal of Andrology, 2020, 22, 427.	0.8	4
858	Clinical activity of abiraterone plus prednisone in docetaxel-naÎ¿ve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2019, 21, 131.	0.8	6
859	Role of Early Dynamic Positron Emission Tomography/Computed Tomography with 68Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with Adenocarcinoma Prostate: Initial Results. Indian Journal of Nuclear Medicine, 2018, 33, 112.	0.1	5
860	Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian Journal of Urology, 2019, 35, 6.	0.2	23
861	Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients. World Journal of Nuclear Medicine, 2019, 18, 244-250.	0.3	11
862	Efficacy and safety of177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia â€“ A prospective study. World Journal of Nuclear Medicine, 2019, 18, 258.	0.3	21
863	Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review. Turkish Journal of Urology, 2019, 45, 245-253.	1.3	9
864	Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection. World Journal of Men?s Health, 2020, 38, 32.	1.7	2
865	Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 506-513.	2.3	33
866	Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics, 2020, 10, 1531-1543.	4.6	34
867	Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Cureus, 2020, 12, e7107.	0.2	9
868	Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer. Cancer Biology and Medicine, 2022, 19, 1193-1210.	1.4	12
869	Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials. Clinical and Experimental Metastasis, 2021, 38, 519-526.	1.7	8
870	Induction of Endoplasmic Reticulum Stress-Mediated Apoptosis by Aminosteroid RM-581 Efficiently Blocks the Growth of PC-3 Cancer Cells and Tumors Resistant or Not to Docetaxel. International Journal of Molecular Sciences, 2021, 22, 11181.	1.8	8
871	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation. European Journal of Medicinal Chemistry, 2022, 227, 113936.	2.6	14

#	Article	IF	Citations
872	Circular RNAs in prostate cancer: Biogenesis, biological functions, and clinical significance. Molecular Therapy - Nucleic Acids, 2021, 26, 1130-1147.	2.3	19
873	Realâ€world use of firstâ€generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castrationâ€resistant prostate cancer. BJU International, 2021, 128, 18-26.	1.3	3
874	Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution. Journal of Radiology and Oncology, 2017, 1, 069-078.	0.2	1
875	Geriatric Oncology in Tropical and Developing Countries. , 2017, , 1-20.		0
876	Roundup. Indian Journal of Urology, 2017, 33, 101.	0.2	0
877	Chemotherapy With Androgen Deprivation for Hormone-NaÃ¯ve Prostate Cancer. The Korean Journal of Urological Oncology, 2017, 15, 11-15.	0.1	0
878	The Trend of Uro-Oncologist About Blood Test and Imaging Studies for the Diagnosis of Biochemical Recurrence in Korea. The Korean Journal of Urological Oncology, 2017, 15, 131-136.	0.1	0
879	Supraclavicular lymph node as the first presentation and late skin metastasis: an unusual clinical course for prostate cancer. Turkish Journal of Urology, 2018, 44, 75-78.	1.3	2
880	Alternative Antiandrogen Therapy for CRPC. , 2018, , 215-223.		0
881	Resection of Metastatic Cancer in Castration-Resistant Patients. , 2018, , 185-195.		0
882	Side Effects of Medical Cancer Therapy in Genitourinary Malignancies. , 2018, , 179-212.		0
883	Prediction of Optimal Number of Cycles in Docetaxel Regimen for Patients with mCRPC. , 2018, , 345-355.		0
884	Recent Trends in Hormone Therapy for Prostate Cancer in Japan. , 2018, , 3-11.		0
886	Effectiveness and safety of abiraterone acetate treatment for metastatic castration-resistant prostate cancer post-chemotherapy. Urologie Pro Praxi, 2018, 19, 61-63.	0.0	0
887	Application of radiolabeled ligands to the prostate-specific membrane antigen for determine localization of biochemical recurrence of prostate cancer by PET/CT (literature review). Medical Visualization, 2018, , 81-97.	0.1	2
888	Knowledge Level About Prostate Cancer Screenings in Turkey. Jundishapur Journal of Chronic Disease Care, 2018, 7, .	0.1	0
889	Salvage SBRT for Local Recurrence of Prostate Cancer After Definitive Radiotherapy. , 2019, , 171-182.		0
891	Have we found an optimal sequence in the treatment of metastatic castrationally-resistant prostate cancer?. Onkologie (Czech Republic), 2018, 12, 217-223.	0.0	0

#	Article	IF	Citations
892	Androgen Deprivation Therapy for Advanced Prostate Cancer. , 2019, , 1-22.		0
893	Technological Advancements in Nuclear Medicine and Molecular Imaging. European Archives of Medical Research, 2018, 34, 25-29.	0.0	0
895	Uroonkologie beim Ã¤lteren Patienten. Springer Reference Medizin, 2019, , 1-10.	0.0	0
896	Management of Nonmetastatic Failure Following Local Prostate Cancer Therapy. , 2019, , 227-240.		0
897	Androgen Deprivation Therapy for Advanced Prostate Cancer. , 2019, , 255-276.		0
898	Impact of functional imaging in prostate cancer: a clinical point of view. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 1-6.	0.4	0
900	Salvage radiation therapy after radical prostatectomy: survival analysis. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 240-248.	3.9	3
901	Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?. European Journal of Hospital Pharmacy, 2021, 28, 83-87.	0.5	1
902	Identification of favorable subgroups for alternative antiâ€‘androgen therapy in castrationâ€‘resistant prostate cancer. Molecular and Clinical Oncology, 2019, 11, 523-530.	0.4	3
903	EvaluaciÃ³n de la biopsia de fusiÃ³n elÃ¡stica vs. biopsia sistemÃ¡tica para la detecciÃ³n del cÃ¡ncer de prÃ³stata: resultados de un estudio multicÃ©ntrico en 1.119 pacientes. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 431-438.	0.3	2
904	Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer. Meditsinskiy Sovet, 2019, , 170-175.	0.1	0
905	Complete scintigraphic resolution of a bone metastasis after androgen-deprivation therapy. Journal of Surgery and Medicine, 0, , .	0.0	1
906	Factores relacionados con la resistencia a la castraciÃ³n precoz en el cÃ¡ncer de prÃ³stata metastÃ¡sico. Resultados del Registro nacional de cÃ¡ncer de prÃ³stata en EspaÃ±a. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 562-567.	0.3	2
909	Special emphasis on bone health management in prostate cancer patients: a prospective longitudinal study. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 363-373.	0.7	2
910	New Androgen Receptor Axis-Targeted Agents in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer: From Bench to Clinical Trials. The Korean Journal of Urological Oncology, 2020, 18, 99-108.	0.1	0
912	Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1731-1742.	3.3	13
913	Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases. Meditsinskiy Sovet, 2020, , 84-88.	0.1	0
914	The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy. Meditsinskiy Sovet, 2020, , 100-108.	0.1	0

#	Article	IF	Citations
916	Should We Reconsider the Necessity of a Refinement of Prostate Cancer Risk Classification and Radiotherapy Treatment Strategy? Experiences from a Retrospective Analysis of Data from a Single Institution. Journal of Clinical Medicine, 2021, 10, 110.	1.0	0
917	A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients. Translational Andrology and Urology, 2020, 9, 2572-2586.	0.6	8
918	Role of Cytoreductive Radical Prostatectomy in the Treatment of Metastatic Prostate Cancer. The Korean Journal of Urological Oncology, 2020, 18, 161-169.	0.1	0
919	Using In Situ Padlock Probe Technology to Detect mRNA Splice Variants in Tumor Cells. Methods in Molecular Biology, 2020, 2148, 361-378.	0.4	2
920	How do we define â€œcastrationâ€•in men on androgen deprivation therapy?. Asian Journal of Andrology, 2020, 22, 441.	0.8	4
921	Molecular mechanisms of docetaxel resistance in prostate cancer. , 2020, 3, 676-685.		11
922	Klinik. , 2020, , 1-7.		0
923	Geriatric Oncology in Tropical and Developing Countries. , 2020, , 939-958.		0
924	The Relationships between Survivals and Early Salvage Androgen Deprivation Therapy for Non-Organ Confined Prostate Cancer after Radical Prostatectomy. Chonnam Medical Journal, 2020, 56, 115.	0.5	0
925	PSA/biparametric MRI: An accurate potential diagnostic approach for detection and management of local recurrence after radical prostatectomy. Turkish Journal of Urology, 2020, 46, 87-88.	1.3	3
926	Next-Generation Sequencing in Prostate Cancer. The Korean Journal of Urological Oncology, 2020, 18, 18-23.	0.1	0
927	Terapia de privaciÃ³n de andrÃ³genos en pacientes con enfermedad localizada: comparaciÃ³n de las opciones de tratamiento y tiempo hasta la resistencia a la castraciÃ³n. Resultados del Registro EspaÃ±ol de CÃ¡ncer de PrÃ³stata. Actas UrolÃ³gicas EspaÃ±olas, 2020, 44, 156-163.	0.3	4
928	High DND1 Level Indicates a Poor Prognostic Factor in Prostate Cancer. Disease Markers, 2021, 2021, 1-7.	0.6	1
929	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. Clinical Genitourinary Cancer, 2022, 20, 43-52.	0.9	3
930	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials, 2021, 22, 768.	0.7	13
932	Focal Salvage Therapy for Prostate Cancer Recurrence After Primary Radiotherapy. , 2021, , 161-180.		0
933	Salvage Lymph Node Dissection. , 2021, , 181-187.		0
934	Role of Metastasectomy in Prostate Cancer Patients Following Primary Treatment. , 2021, , 211-221.		0

#	Article	IF	Citations
935	Imaging for Salvage Therapy in Recurrent Prostate Cancer. , 2021, , 79-87.		0
936	Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway. Nuclear Medicine Communications, 2021, 42, 332-336.	0.5	15
937	Implication of Prophetic Variables and their Impulsive Interplay in CA Prostate Patients Experiencing Osteo-Metastasis. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 2106-2113.	0.9	2
939	The Prognostic Factors of Biochemical Recurrence-Free Survival Following Radical Prostatectomy. Asian Pacific Journal of Cancer Prevention, 2017, 18, 2555-2559.	0.5	2
940	Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 351-359.	1.0	9
941	Targeting prostate cancer cell proliferation, stemness and metastatic potential using derived phytochemicals. American Journal of Translational Research (discontinued), 2019, 11, 2550-2569.	0.0	3
942	The role of radiotherapy in metastatic prostate cancer. American Journal of Clinical and Experimental Urology, 2019, 7, 92-97.	0.4	2
943	Current and Future Management of Locally Advanced and Metastatic Prostate Cancer. Reviews in Urology, 2020, 22, 110-123.	0.9	4
944	Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate. Indian Journal of Urology, 2021, 37, 72-78.	0.2	0
945	Exploratory study of F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 218-229.	1.0	1
946	A prospective longitudinal study to evaluate bone health, implication of FRAX tool and impact on quality of life (FACT-P) in advanced prostate cancer patients. American Journal of Clinical and Experimental Urology, 2021, 9, 211-220.	0.4	0
947	Basics in Magnetic Resonance guided Focused Ultrasound: technical basis and clinical application. A brief overview. Acta Biomedica, 2021, 92, e2021403.	0.2	0
948	The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report. Acta Biomedica, 2021, 92, e2021214.	0.2	0
949	Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. Translational Oncology, 2022, 15, 101292.	1.7	7
950	The relationship between 68Ga-PSMA uptake and Gleason Score and PSA levels in patients with prostate cancer. Anatolian Current Medical Journal:, 2021, 3, 327-332.	0.1	0
951	⁶⁸Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy. Journal of Nuclear Medicine, 2022, 63, 1191-1198.	2.8	22
952	Estudio multicÃ©ntrico sobre los comitÃ©s multidisciplinarios en cÃ¡ncer de prÃ³stata avanzado. Actas UrolÃ³gicas EspaÃ±olas, 2022, 46, 106-113.	0.3	0
953	Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years. Clinical Oncology, 2022, 34, 50-56.	0.6	7

#	Article	IF	Citations
954	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 778858.	1.3	7
955	177Lu-PSMA-617 versus docetaxel in chemotherapy-naÃ¯ve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1754-1764.	3.3	25
956	Effectiveness of cognitive behavioural therapy on quality of life in patients with prostate cancer after androgen deprivation therapy: a protocol for systematic review and meta-analysis. BMJ Open, 2021, 11, e049314.	0.8	1
957	Moving Forward: Expected Opportunities for the Development of New Therapeutic Agents. , 2022, , 495-534.		0
958	Phase I clinical trial of HCâ€1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of singleâ€dose proportionality and effects of food. Prostate, 2021, , .	1.2	3
959	Predicting Cancer-Specific Survival Among Patients With Prostate Cancer After Radical Prostatectomy Based on the Competing Risk Model: Population-Based Study. Frontiers in Surgery, 2021, 8, 770169.	0.6	3
960	[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer. EJNMMI Research, 2021, 11, 119.	1.1	7
961	Fiducial markers and their impact on ablation outcome for patients treated with MR-guided transurethral ablation (TULSA): a retrospective technical analysis. International Journal of Hyperthermia, 2021, 38, 1677-1684.	1.1	1
962	Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis. Clinical and Translational Oncology, 2022, 24, 1177-1183.	1.2	7
963	The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment. Seminars in Nuclear Medicine, 2022, 52, 255-262.	2.5	8
964	Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. Oncologist, 2022, 27, 220-227.	1.9	5
965	Systemtherapie des mCRPC. , 2021, , 339-360.		0
967	Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET/CT. Diagnostics, 2022, 12, 195.	1.3	5
968	Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. Prostate International, 2022, 10, 21-27.	1.2	3
969	MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data. British Journal of Cancer, 2022, 126, 502-513.	2.9	28
970	Predictive Value of Circulating Tumor Cells Detected by ISETÂ® in Patients with Non-Metastatic Prostate Cancer Undergoing Radical Prostatectomy. Life, 2022, 12, 165.	1.1	1
971	Perception of castration value over cost in the metastatic prostate cancer scenario: a contemporary pharmacoeconomic perspective. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 175-179.	0.7	3
972	Stromal Fibroblasts Counteract the Caveolin-1-Dependent Radiation Response of LNCaP Prostate Carcinoma Cells. Frontiers in Oncology, 2022, 12, 802482.	1.3	2

#	Article	IF	Citations
973	Evaluation of machine learning strategies for imaging confirmed prostate cancer recurrence prediction on electronic health records. Computers in Biology and Medicine, 2022, 143, 105263.	3.9	6
974	Androgen receptorâ€mediated transcriptional repression targets cell plasticity in prostate cancer. Molecular Oncology, 2022, 16, 2518-2536.	2.1	2
975	Multicenter study on multidisciplinary committees in advanced prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2022, 46, 106-106.	0.2	0
976	Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells. Frontiers in Oncology, 2022, 12, 789284.	1.3	13
977	Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Medical Informatics and Decision Making, 2022, 22, 35.	1.5	8
978	Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinomaâ€"Progress and Challenges. Vaccines, 2022, 10, 276.	2.1	1
979	Useful predictors of progressionâ€free survival for Japanese patients with LATITUDEâ€highâ€risk metastatic castrationâ€sensitive prostate cancer who received upfront abiraterone acetate. International Journal of Urology, 2022, 29, 229-234.	0.5	8
980	Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer. Frontiers in Pharmacology, 2021, 12, 736951.	1.6	8
981	Clinical utility of F-Fluciclovine PET/CT in recurrent prostate cancer with very low (â‰0.3 ng/mL) prostate-specific antigen levels. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 406-414.	1.0	2
982	Alpha-Emitter Radiopharmaceuticals and External Beam Radiotherapy: A Radiobiological Model for the Combined Treatment. Cancers, 2022, 14, 1077.	1.7	0
983	Adapalene Inhibits Prostate Cancer Cell Proliferation In Vitro and In Vivo by Inducing DNA Damage, S-phase Cell Cycle Arrest, and Apoptosis. Frontiers in Pharmacology, 2022, 13, 801624.	1.6	6
984	Radium-223 in mCPRC patients: a large real-life Italian multicenter study. Minerva Urology and Nephrology, 2022, 74, .	1.3	3
986	MicroRNAs as Potential Liquid Biopsy Biomarker for Patients with Castration-Resistant Prostate Cancer. Research and Reports in Urology, 2022, Volume 14, 63-70.	0.6	3
987	Comparison of 68Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer. European Journal of Hybrid Imaging, 2022, 6, 5.	0.6	5
988	Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis. Radiologia Medica, 2022, 127, 449-457.	4.7	11
989	Genetic variant located on chromosome 17p12 contributes to prostate cancer onset and biochemical recurrence. Scientific Reports, 2022, 12, 4546.	1.6	2
990	The slope associated with nadir prostateâ€specific antigen is prognostically significant in men with hormoneâ€sensitive prostate cancer after primary androgen deprivation therapy. Cancer Medicine, 2022, , .	1.3	1
991	¹⁸F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study. Journal of Nuclear Medicine, 2022, 63, 1208-1214.	2.8	2

#	Article	IF	Citations
992	Exosomal LINC01213 Plays a Role in the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manners. Journal of Oncology, 2022, 2022, 1-9.	0.6	7
993	An Overview of siRNA Delivery Strategies for Urological Cancers. Pharmaceutics, 2022, 14, 718.	2.0	5
994	Imaging of Oligometastatic Disease. Cancers, 2022, 14, 1427.	1.7	4
995	Definition of Castrate Resistant Prostate Cancer: New Insights. Biomedicines, 2022, 10, 689.	1.4	18
996	The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 126-135.	0.1	1
997	Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers. Research and Reports in Urology, 2022, Volume 14, 87-108.	0.6	13
998	Validation of¹⁸F-rhPSMA-7 and¹⁸F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine, 2022, 63, 1809-1814.	2.8	8
999	Targeting the androgen receptor signaling pathway in advanced prostate cancer. American Journal of Health-System Pharmacy, 2022, 79, 1224-1235.	0.5	5
1001	First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry. Tumori, 2023, 109, 224-232.	0.6	3
1002	Uptake of ¹⁸F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 205-213.	0.7	3
1003	Treatment of complex urethral stenosis in public centers from developing countries in 21st century. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 349-353.	0.7	1
1004	Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage. Radiotherapy and Oncology, 2022, 169, 71-76.	0.3	6
1005	A novel upper tract ureteroscopic biopsy technique: the â€œform tackleâ€• International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 367-368.	0.7	2
1006	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. ESMO Open, 2022, 7, 100431.	2.0	1
1007	Indications and timing of radiotherapy after radical prostatectomy: An update. , 2021, 1, 17-18.		0
1008	Impact of mpMRI targeted biopsy on intraoperative nerveâ€sparing (NeuroSAFE) during robotâ€assisted laparoscopic radical prostatectomy. Prostate, 2022, 82, 493-501.	1.2	4
1009	The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance. International Journal of Molecular Sciences, 2022, 23, 392.	1.8	15
1010	The Mangrove-Derived Diterpenoid Diaporthe B Inhibits the Stemness and Increases the Efficacy of Docetaxel in Prostate Cancer PC-3 Cells. Natural Product Communications, 2021, 16, 1934578X2110496.	0.2	1

#	Article	IF	Citations
1011	Insights of RKIP-Derived Suppression of Prostate Cancer. Cancers, 2021, 13, 6388.	1.7	6
1012	Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts. Radiotherapy and Oncology, 2022, 170, 213-223.	0.3	8
1013	Postoperative radiotherapy in prostate cancer: When and how?Ââ€“ÂAn update review. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, , .	0.6	1
1014	LHRH sparing therapy in patients with chemotherapy-naÃ¯ve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 778-784.	2.0	7
1015	Role of 68Ga and 18F PSMA PET/CT and PET/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies. Nuclear Medicine Communications, 2022, 43, 631-637.	0.5	6
1016	The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml. Nuklearmedizin - NuclearMedicine, 2022, 61, 120-129.	0.3	3
1029	Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate. Indian Journal of Urology, 2021, 37, 72.	0.2	1
1031	High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice. IScience, 2022, 25, 104287.	1.9	4
1032	Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone. Cancers, 2022, 14, 2313.	1.7	3
1033	Diagnostic yield of multiparametric MRI for local recurrence at biochemical recurrence after radical prostatectomy. Prostate International, 2022, 10, 135-141.	1.2	4
1034	Tumour microenvironment and focal therapy for prostate cancer. Current Opinion in Urology, 2022, 32, 248-253.	0.9	1
1035	Implementing and Evaluating the Impact of BoneRx: A Healthy Bone Prescription for Men with Prostate Cancer Initiating Androgen Deprivation Therapy. Journal of Clinical Medicine, 2022, 11, 2703.	1.0	5
1037	Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery. European Urology Open Science, 2022, 40, 117-124.	0.2	1
1038	From Therapy Resistance to Targeted Therapies in Prostate Cancer. Frontiers in Oncology, 2022, 12, .	1.3	10
1039	Current Trends in Advanced Prostate Cancer Medical Setting. Proceedings of the Latvian Academy of Sciences, 2022, 76, 168-180.	0.0	0
1040	The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence. Frontiers in Endocrinology, 2022, 13, .	1.5	1
1042	Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data. Annals of Surgical Oncology, 2022, 29, 7206-7215.	0.7	3
1043	Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study. Biomedicines, 2022, 10, 1321.	1.4	5

#	Article	IF	Citations
1044	Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275). , 2022, 39, .		2
1045	Development and validation of a nomogram for predicting the likelihood of metastasis in prostate cancer patients undergoing Ga-68 PSMA PET/CT due to biochemical recurrence. Nuclear Medicine Communications, 2022, 43, 952-958.	0.5	2
1046	Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. Japanese Journal of Clinical Oncology, 0, , .	0.6	3
1047	Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer. Cancer Medicine, 0, , .	1.3	3
1048	Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers. Acta Radiologica, 2023, 64, 1228-1237.	0.5	3
1049	<scp>Pathological predictors of ¹⁸Fâ€DCFPyL prostateâ€specific membrane antigen</scp>â€<scp>positive recurrence after radical prostatectomy</scp>. BJU International, 2022, 130, 28-36.	1.3	5
1050	Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719). Radiologia Medica, 2022, 127, 912-918.	4.7	5
1051	Diagnostic performance of positron emission tomography combined with computed tomography with 18F-PSMA-1007 for detecting local recurrence of prostate cancer after radical prostatectomy. Proceedings of the National Academy of Sciences of Belarus, Medical Series, 2022, 19, 151-159.	0.2	0
1052	A Novel Angiogenesis-Related Gene Signature to Predict Biochemical Recurrence of Patients with Prostate Cancer following Radical Therapy. Journal of Oncology, 2022, 2022, 1-13.	0.6	0
1053	Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 0, , .	2.0	4
1054	Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance. Molecular Cancer, 2022, 21, .	7.9	29
1055	Functional roles of E3 ubiquitin ligases in prostate cancer. Journal of Molecular Medicine, 2022, 100, 1125-1144.	1.7	6
1056	Effects of estradiol on bone in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial. European Journal of Endocrinology, 2022, 187, 241-256.	1.9	2
1057	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open, 2022, 7, 100518.	2.0	10
1058	Salvage involved-field and extended-field radiotherapy in PET-positive nodal recurrent prostate cancer: outcomes and patterns of failure. Advances in Radiation Oncology, 2022, , 101040.	0.6	0
1060	Prognostic role of panâ€immuneâ€inflammation value in patients with metastatic castrationâ€resistant prostate cancer treated with androgen receptorâ€signaling inhibitors. Prostate, 2022, 82, 1456-1461.	1.2	15
1061	Fever as a first presentation of castration-resistant prostate cancer: A case report. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.4	2
1062	Evaluation of ¹¹Câ€choline positron emission tomography/computed tomography for determining treatment response in castrationâ€resistant prostate cancer patients. International Journal of Urology, 2022, 29, 1072-1078.	0.5	3

#	Article	IF	Citations
1063	Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer. Cancers, 2022, 14, 3744.	1.7	10
1064	Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 3398-3407.	1.8	8
1065	Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	0
1066	Canadian Association of Radiologists Prostate MRI White Paper. Canadian Association of Radiologists Journal, 2022, 73, 626-638.	1.1	1
1067	Machine-Learning-Based Digital Twin System for Predicting the Progression of Prostate Cancer. Applied Sciences (Switzerland), 2022, 12, 8156.	1.3	4
1068	Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1661-1668.	1.4	3
1069	Factors influencing survival in metastatic castration-resistant prostate cancer therapy. Expert Review of Anticancer Therapy, 2022, 22, 1061-1079.	1.1	2
1070	Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience. Radiation Oncology Journal, 2022, 40, 192-199.	0.7	1
1071	Synergistic effects of natural products in combination with anticancer agents in prostate cancer: A scoping review. Frontiers in Pharmacology, 0, 13, .	1.6	7
1072	Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1011-1027.	1.8	3
1073	A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. European Journal of Cancer, 2022, 175, 110-119.	1.3	4
1074	Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial. Cancer Control, 2022, 29, 107327482211204.	0.7	0
1075	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
1076	Added value of shear-wave elastography in the prediction of extracapsular extension and seminal vesicle invasion before radical prostatectomy. Asian Journal of Andrology, 2022, .	0.8	1
1077	Diagnostic value of 3.0 T versus 1.5 T MRI in staging prostate cancer: systematic review and meta-analysis. Polish Journal of Radiology, 2022, 87, 421-429.	0.5	4
1078	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
1079	Single tertiary cancer center experience on the management of pT3b prostate cancer after robotic-assisted laparoscopic prostatectomy. Current Urology, 0, Publish Ahead of Print, .	0.4	0
1081	Construction of miRNA-mRNA network and a nomogram model of prognostic analysis for prostate cancer. Translational Cancer Research, 2022, 11, 2562-2571.	0.4	1

#	Article	IF	Citations
1082	Long Term Results of Elective Nodal Salvage Radiotherapy in Oligometastatic Prostate Cancer : A Mono-Institutional Series. Annals of Urologic Oncology, 2022, , .	0.0	0
1083	Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer. Cancer Imaging, 2022, 22, .	1.2	7
1084	Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment. Molecular Cancer Research, 2022, 20, 1739-1750.	1.5	3
1087	Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. Prostate Cancer, 2022, 2022, 1-12.	0.4	3
1088	Establishment of a <scp>fiveâ€enzalutamideâ€resistanceâ€relatedâ€geneâ€based</scp> classifier for <scp>recurrenceâ€free</scp> survival predicting of prostate cancer. Journal of Cellular and Molecular Medicine, 2022, 26, 5379-5390.	1.6	1
1089	Chromosomal Instability in Cell-free DNA as a Prognostic Biomarker of Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy. European Urology Focus, 2023, 9, 89-95.	1.6	1
1090	Prostate-Specific Membrane Antigen-Based PET Brings New Insights into the Management of Prostate Cancer. PET Clinics, 2022, , .	1.5	0
1091	Computer classification and construction of a novel prognostic signature based on moonlighting genes in prostate cancer. Frontiers in Oncology, 0, 12, .	1.3	3
1093	Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial. European Journal of Endocrinology, 2022, 187, 617-627.	1.9	2
1094	How can we best manage biochemical failure after radical prostatectomy?. Investigative and Clinical Urology, 2022, 63, 592.	1.0	1
1095	Definitions of â€œcureâ€•after LDR-brachytherapy in low- and intermediate-risk prostate cancer - Phoenix or surgical?. Advances in Radiation Oncology, 2022, , 101112.	0.6	0
1096	Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry. Prostate Cancer and Prostatic Diseases, 2023, 26, 162-169.	2.0	3
1097	Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis. Clinical Genitourinary Cancer, 2023, 21, e27-e34.	0.9	1
1099	Study on the role of SLC14A1 gene in biochemical recurrence of prostate cancer. Scientific Reports, 2022, 12, .	1.6	0
1100	The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer. Cancers, 2022, 14, 4877.	1.7	12
1101	Stroma biglycan expression can be a prognostic factor in prostate cancers. International Journal of Urology, 2023, 30, 147-154.	0.5	3
1103	Identification and validation of a lipid metabolism gene signature for predicting biochemical recurrence of prostate cancer after radical prostatectomy. Frontiers in Oncology, 0, 12, .	1.3	1
1104	Hospital-based prostate cancer screening in vietnamese men with lower urinary tract symptoms: a classification and regression tree model. BMC Urology, 2022, 22, .	0.6	0

#	Article	IF	Citations
1106	Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus¹⁸F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial. Journal of Nuclear Medicine, 2023, 64, 586-591.	2.8	2
1107	Minimal Residual Disease (MRD) and a New Immunotherapy in Locally Advanced Prostate Cancer. , 2022, , .		0
1108	Radioresistance Mechanisms in Prostate Cancer Cell Lines Surviving Ultra-Hypo-Fractionated EBRT: Implications and Possible Clinical Applications. Cancers, 2022, 14, 5504.	1.7	1
1109	Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
1110	Evaluation of factors predicting response to abiraterone acetate in metastatic castration-resistant prostate cancer: A prospective study. Journal of Clinical Urology, 0, , 205141582211297.	0.1	0
1111	Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec. Current Oncology, 2022, 29, 8626-8637.	0.9	2
1112	Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. European Urology, 2023, 83, 521-533.	0.9	10
1113	Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2023, 26, 180-187.	2.0	5
1115	Effectiveness of 11C-choline PET/CT in prostate cancer surveillance. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2023, 42, 93-99.	0.1	0
1116	Kinetic Analysis of Prostate-Specific Antigen Interaction with Monoclonal Antibodies for Development of a Magnetic Immunoassay Based on Nontransparent Fiber Structures. Molecules, 2022, 27, 8077.	1.7	4
1117	Nomograms predict survival benefits of radical prostatectomy and chemotherapy for prostate cancer with bone metastases: A SEERâ€based study. Frontiers in Oncology, 0, 12, .	1.3	1
1118	Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer. Cancers, 2022, 14, 6009.	1.7	2
1119	Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET. Cancers, 2022, 14, 6194.	1.7	6
1120	The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort. Prostate Cancer and Prostatic Diseases, 2024, 27, 89-94.	2.0	3
1121	Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatmentâ€"Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1487-1498.	3.3	6
1123	Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy. Frontiers in Oncology, 0, 12, .	1.3	5
1124	High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade. British Journal of Cancer, 2023, 128, 1267-1277.	2.9	4
1125	Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China. PeerJ, 0, 11, e14500.	0.9	1

#	Article	IF	Citations
1126	Development and validation of a novel risk model in newly diagnosed de novo bone metastatic prostate cancer (M1b): a retrospective study. PeerJ, 0, 11, e14615.	0.9	1
1127	Molecular Mechanisms of Noncoding RNA in the Occurrence of Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences, 2023, 24, 1305.	1.8	2
1128	Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. Frontiers in Genetics, 0, 13, .	1.1	6
1129	Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?. Cancers, 2023, 15, 323.	1.7	2
1130	(18F)-PSMA-1007PET/CT in patients with biochemical recurrence after radical prostatectomy: Diagnostic performance and impact on treatment management. , 2023, 5, 100021.		1
1131	Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies. Anticancer Research, 2023, 43, 323-333.	0.5	3
1132	S-PI-RADS and PI-RRADS for Biparametric MRI in the Detection of Prostate Cancer and Post-treatment Local Recurrence. Anticancer Research, 2023, 43, 297-303.	0.5	1
1133	PSMA PET/CT imaging for biochemical recurrence of prostate cancer after radiotherapy: is it necessary to review the Phoenix criteria?. Clinical and Translational Imaging, 0, , .	1.1	0
1134	Understanding biochemical recurrence after radical prostatectomy: trust biology, not a number. Prostate Cancer and Prostatic Diseases, 2023, 26, 637-638.	2.0	1
1135	Analysis of Risk Factors for Early Progression of Prostate Cancer After Initial Endocrine Therapy. Journal of Cancer, 2023, 14, 519-531.	1.2	0
1136	Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study. BMC Medicine, 2023, 21, .	2.3	0
1137	Ferroptosisâ€™s Role in Genitourinary System Cancer. Oncologie, 2022, 24, 679-691.	0.2	8
1138	A nomogram model for determining optimal patients for local therapy in metastatic prostate cancer: a SEER database-based study. BMC Urology, 2023, 23, .	0.6	1
1140	Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer. Clinical Chemistry, 2023, 69, 386-398.	1.5	7
1141	Prognostic value of genomic mutations in metastatic prostate cancer. Heliyon, 2023, 9, e13827.	1.4	3
1142	Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer. Biology Bulletin, 2022, 49, 2285-2297.	0.1	0
1143	Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2188-2195.	3.3	4
1144	Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers. International Journal of Molecular Sciences, 2023, 24, 4601.	1.8	2

#	Article	IF	Citations
1145	Deep, rapid, and durable prostate-specific antigen decline with apalutamideÂplus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Annals of Oncology, 2023, 34, 477-485.	0.6	16
1147	Experiences of Men With Prostate Cancer Participating in a Clinical Pathway With a Supervised Group-based Exercise Program to Combat Androgen Deprivation-Induced Side Effects: A Qualitative Focus Group Study. Seminars in Oncology Nursing, 2023, , 151404.	0.7	0
1148	Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy. Cancer Imaging, 2023, 23, .	1.2	9
1149	A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. Cancer Immunology, Immunotherapy, 2023, 72, 2357-2373.	2.0	3
1150	An approach to genetic testing in patients with metastatic castration-resistant prostate cancer in Singapore. Annals of the Academy of Medicine, Singapore, 2023, 52, 135-148.	0.2	1
1151	Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?. Current Urology Reports, 0, , .	1.0	0
1152	Biochemically recurrent prostate cancer: rationalisation of the approach to imaging. Clinical Radiology, 2023, , .	0.5	0
1153	Predictive factors for disease progression after salvage radiation therapy in biochemical recurrent patients treated by radical prostatectomy. Prostate International, 2023, 11, 145-149.	1.2	1
1154	Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide. Clinical Genitourinary Cancer, 2023, 21, e362-e369.	0.9	1